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3. Abstract 
Acute myeloid leukaemia  (AML) is a genetic heterogeneous group of diseases, with the 
largest subgroup showing a mutation in the Nucleophosmin gene (NPM1). Normally the 
NPM protein localizes mainly in the nucleolus, but in AML blasts it is aberrant localized to 
the cytoplasm (NPMc+AML). Notably, NPMc+AML patients show peculiar gene 
expression profiles, treatment response and prognosis. Hence, it has been proposed as an 
independent category for leukaemia classification according to WHO in 2008. In view of 
the relevance of NPMc+ mutation to AML pathogenesis and prognosis, understanding its 
role in leukaemia development represents a major issue in the field. 
The aim of this PhD project is to get further insight into the relevance of NPMc+ 
mutations to AML development. To this scope, here it is reported a characterization of a 
novel mouse model expressing the mutated protein. The hematopoietic restricted 
expression of the protein induces leukaemia in mice. This data definitively clarify that 
NPMc+ is an initiating mutation for leukaemia development. However, the long latency 
and low penetrance of disease onset strongly support the need of cooperating mutations. 
Since, the high frequency of FLT3-ITD mutations in NPMc+AML, we genetically tested 
the synergisms between the two abnormalities. To this scope, NPMc+ mice were crossed 
with FLT3-ITD mice (Lee, 2007). Double mutated mice developed leukaemia with sort 
latency and full penetrance indicating effective cooperation. Moreover, our data support 
the two hits model of tumourigenesis, where functional complementary mutations 
contribute to disease onset. 
Another major challenge of this project is to understand how NPMc+ affect the biology of 
normal HSPC and imposes the transition from normal to cancer stem cells. We found that 
NPMc+ expression perturbs the homeostasis of HSCP and expand the number of LT-
HSC by increasing the proliferation rate. However, this enhanced proliferation is not 
associated to loss of quiescent and functional HSC, which may represent a reservoir of 
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persistent pre-malignant cells available for the accumulation of additional genetic alteration. 
Further investigation into the biology of per-leukaemic stem cells may give insights into the 
molecular mechanisms imposed by the oncogene for malignancy transformation and finally 
may contribute for the development of new therapeutic strategies. 
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4.1.  Nucleophosmin (NPM) 
Nucleophosmin (NPM) is an abundant phosphoprotein originally identified as a non-
ribosomal nucleolar phosphoprotein that resides within the granular regions of the 
nucleolus (Kang et al, 1974; Spector et al, 1984). NPM is ubiquitously expressed and highly 
conserved in vertebrates and it mainly acts as a nucleolar chaperone able to shuttle between 
nucleus and cytoplasm. Since its identification, several studies have uncovered the complex 
biology of NPM showing its involvement in different cellular processes such as ribosome 
biogenesis, genomic stability, response to stress stimuli and regulation of crucial tumour 
suppressor as ARF (Colombo et al, 2005) and oncogene as c-MYC (Bonetti et al, 2008). 
Notably, targeting disruption of the NPM1 gene in mouse showed its essential function 
during the embryogenesis and, in particular, for the haematopoiesis and brain development 
(Grisendi et al, 2005). 
The interest in NPM has grown following the report published in January 2005 with the 
contribution of our laboratory of cytoplasmic accumulation of NPM (NPM1c+) associated 
with mutations in the 3’ end of the gene in up to 35% of cases with acute myeloid 
leukaemia (AML; 60% of patients presenting with normal karyotype). This PhD project 
constitutes an attempt at further characterization of NPM functions acquired in the 
presence of the mutation in order to better the understanding of the pathogenesis of AML. 
 
4.1.1. NPM1  gene and protein structure 
The nucleophosmin protein, also known as B23 (Yung et al, 1985), numatrin (Feuerstein & 
Mond, 1987) or NO38 (Schmidt-Zachmann et al, 1987) is the product of the NPM1 gene. 
In the human genome it maps to the chromosome 5q35, spans 25kb and contains 12 exons 
with sizes raging form 58 to 358 bp. Two alternative splicing isoforms, NPM1 (or B23.1) 
and NPM1.2 (or B23.2), have been identified form the NPM1 transcript (Wang et al, 1993) 
(Figure 1). In the long isoform, NPM1 (or B23.1), exon 9 is spliced to exon 11 and the 
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coding sequence stops at the exon 12, resulting in a protein of 294 residues. The short 
isoform, NPM1.2, is a truncated protein of 259 residues. For this variant, exon 9 is joined 
to exon 10 that contains an alternative stop codon, thus the translation stops sooner giving 
rise to a protein differing from the long isoform in its carboxy-terminal part (Chang & 
Olson, 1990; Wang et al, 1993). The prevalent form expressed in all tissues is the long 
isoform that is characterized by abundant expression and the predominant nucleolar 
localization. The short isoform is expressed at lower level and it is detected mainly in the 
nucleoplasm. However, its biological significance and physiological function remains 
largely unknown (Wang et al, 1993). In the human EST database a further transcript variant 
lacking exon 8 has been identified (GenBank accession number: NM_199185). This variant 
of 265 residues results in a shorter protein that lacks an internal segment. Its function and 
its tissue distribution are currently totally uncertain. 
 
	  
Figure 1 - Schematic representation of the human NPM1  gene and NPM isoforms variants 1, 2 and 
3. Numbers 1-12 represents positions of the exons. The lines in the scheme represent multiple alternative 
splicing events. Blue and yellow regions represent coding sequence and untranslated regions respectively 
(modified from Lim and Wang, 2006). 
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The NPM polypeptide chain has a modular structure containing distinct sequence motifs 
underlying different functional domains (Figure 2). Starting from the N-terminus, the NPM 
protein contains a hydrophobic segment that is involved in homo-oligomerization (Herrera 
et al, 1996) as well as in chaperone activity. Indeed, under native conditions, NPM forms 
oligomers, preferentially pentamers and decamers (Namboodiri et al, 2004). Sequence 
analysis has identified in this region a hydrophobic leucine-rich nuclear export signal (NES) 
motif (LxxPxxLxLx). This non-polar region is followed by two acid stretches that are 
important for histone binding. The central portion between the two acidic domains is 
required for ribonuclease activity, together with the C-terminal domain that contains basic 
regions involved in nucleic-acid binding (Hingorani et al, 2000).  The central portion of the 
protein contains a bipartite nuclear localization signal (NLS) motif. Importantly, in the long 
isoform alone, the basic cluster is followed by an aromatic stretch, which contains two 
crucial tryptophan residues (288 and 290) that define a nucleolar localization signal (NoLS) 
(Nishimura et al, 2002). The presence of both a NES and NLS signals allows for the 
continuous and rapid shuttling of NPM between the nucleus and the cytoplasm (Borer et 
al, 1989). 
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Figure 2 - Schematic representation of the NPM protein. 
The different functional domains are indicated and the colour tags are explained in the box. NES: nuclear 
export signal. NLS: nuclear localization signal NoLS: nucleolar localization signal (modified from Grisendi et 
al, 2006). 	  
4.1.2. NPM functions  
Thanks to different functional domains and its ability to shuttle between the nucleus and 
the cytoplasm, NPM has been reported to take part in several cellular processes. 
4.1.2.1. NPM chaperone activities  
Molecular chaperones are proteins that assist the non-covalent folding and assembly 
among charged molecules within cells, such as nuclear acids or proteins. In this way they 
prevent aggregation and formation of non-specific complexes. 
NPM is a member of the Nucleophosmin/Nucleoplasmin (Np) family of nuclear 
chaperones, which all share a conserved N-terminal domain (Frehlick et al, 2007). In 
accordance, several in vitro functional studies have reported that NPM behaves like a 
molecular chaperone on many different substrates (Szebeni & Olson, 1999). Unlike 
classical molecular chaperone, such as Hsp70 and chaperonins, that release their substrate 
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using an ATP-dependent mechanisms (Ruddon & Bedows, 1997), in vitro experiments 
showed that the interaction between NPM and its partners is governed by simple 
association-dissociation thermodynamics, and is not an ATP-dependent process (Szebeni 
& Olson, 1999). However, it has been observed that NPM is able to bind ATP in vitro 
(Chang et al, 1998). In vitro experiments have shown that NPM binds histones and transfers 
them to relaxed open circular DNA, suggesting a role during the assembly of nucleosome 
(Okuwaki et al, 2001). Histone chaperones have also been suggested to play a role in 
removal of histones, during transcriptional activation. In accordance with this, it has been 
shown that NPM is able to promote nucleosomal disruption (Swaminathan et al, 2005). It 
seems, therefore, that NPM through its chaperone activity, can influence the transcriptional 
activity of the cells even if the detailed molecular mechnisms are not compleately 
understood. Importantly, NPM regulates the half-life and the cellular localization of many 
of its binding partners, including ARF (Kuo et al., 2004; Colombo et al, 2005) and F-box 
and WD repeat domain containing 7 (Fbw7γ) (Bonetti et al, 2008) and the 
SUMO/sentrin/SMT3 specific peptidases 3 and 5 (SENP3-5) (Yun et al, 2008) and 
influences the stability of the cell cycle inhibitor p21/WAF/CIF (p21) (Xiao et al, 2009). 
 
4.1.2.2. NPM and ribosome biogenesis 
Originally, NPM was identified as protein localized in the granular region of nucleolus. For 
this reason it was believed to be involved in the later stages of ribosome biogenesis 
(Spector et al, 1984). Additional immunoelectron microscopy studies have revealed that 
NPM was also present in the dense fibrillar component of the nucleolus (Biggiogera et al, 
1989). This region is involved in the processing and maturation of the pre-rRNA 
transcripts, suggesting a possible involvement of NPM in the initial steps of ribosome 
biogenesis. It has been shown that NPM, while shuttling between nucleus and cytoplasm, 
forms specific complexes with other nucleolar proteins such as nucleolin (Li et al, 1996), 
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p120 protein (Valdez et al, 1994) and HIV-1 Rev protein (Fankhauser et al, 1991). It has 
been also demonstrated that in vitro NPM is able to stimulate the nuclear import of 
different substrates (Szebeni et al, 1997), containing a Nuclear Localization Signal (NLS). 
According to these data, it has been proposed a possible role of NPM not only in ribosome 
assembly but also in the transport of ribosomal and other proteins both inside and outside 
the nucleolus. Furthermore, in vitro studies showed that NPM has an intrinsic ribonuclease 
activity (Herrera et al, 1996; Herrera et al, 1995). In particular, Savkur and colleagues 
demonstrated that NPM preferentially cleaves pre-rRNA at a specific site in the internal 
transcribed spacer number two (ITS2), located 3’ to the 5.8S rRNA domain in 32S pre-
RNA contributing to the maturation of the rRNA precursors (Savkur & Olson, 1998). 
Taken together, NPM is involved at different stages of ribosome biogenesis, maturation of 
rRNA precursors, and in the trafficking of essential components for ribosome biogenesis. 
However, it is worth noting that mouse embryonic fibroblasts (MEFs) from mouse lacking 
the expression of NPM and the tumour suppressor protein p53 are able to grow under 
culture conditions, thus suggesting that NPM it is not “absolutely required” for ribosomal 
biogenesis in living cells (Bonetti et al, 2008). 
 
4.1.2.3. NPM and cellular proliferation and survival 
NPM is generally considered a protein that promotes cellular growth and survival upon 
apoptotic/stress stimuli and it appears to regulate these functions in a cell specific manner 
(Colombo et al, 2011).  Indeed, NPM protein level increases in cells that are actively cycling 
(Dergunova et al, 2002) and in many solid tumour (Grisendi et al, 2006). In fact, NPM has 
been reported to be overexpressed in colon (Nozawa et al, 1996), gastric (Tanaka et al, 
1992), ovarian (Shields et al, 1997) and prostate (Subong et al, 1999) carcinomas, and in 
some cases the NPM mRNA level correlates with disease progression (Tsui et al, 2004). On 
the other hand, NPM protein levels decrease when cells are induced to differentiate and the 
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down-regulation of the NPM mRNA delays mitosis entry (Jiang & Yung, 1999). 
Furthermore, the proliferation is severely impaired and apoptosis is induced in NPM1 
deficient cells (Colombo 2002) or when NPM nuclear-cytoplasmic shuttling is inhibited 
(Brady et al, 2004; Grisendi et al, 2005). NPM is involved in proliferation-promoting 
pathways through different mechanisms. Notably, the NPM1 gene is a transcriptional 
target of the c-MYC proto-oncogene and the NPM has been correlated with the 
stimulation of DNA polymerase-α activity. In addition, several studies have shown that 
NPM overexpression promotes cell survival in immortal cell lines through the inhibition of 
specific pro-apoptotic pathways, even though there is no evidence of a direct involvement 
of NPM in the regulation of the apoptotic machinery. It is likely that NPM acts as an anti-
apoptotic protein through indirect mechanisms (Figure 3). In accordance, it has been 
shown that, in the neuronal PC12 cell line, NPM is required for the anti-apoptotic function 
of the nerve growth factor (NGF) by inhibiting the DNA fragmentation capacity of the 
caspase activated DNase (CAD) (Ahn et al, 2005). Another pathway through which NPM 
exerts an anti-apoptotic response engages the interferon inducible double-stranded RNA-
dependent protein kinase (PKR). PKR is an antiviral-response protein that is able to inhibit 
mRNA translation through the phosphorylation and inactivation of eukaryotic translation 
initiation factor 2α (EIF2α). Normally, PKR initiates apoptosis in response to different 
cellular and extra-cellular signals (Jagus et al, 1999). NPM binds PRK and inhibits its pro-
apoptotic activities (Pang et al, 2003). Furthermore, it has been demonstrated that although 
NPM overexpression stabilized the p53 tumour suppressor protein, it prevented the 
proapoptotic accumulation of p53 in the mitochondria, thus reducing apoptotic response 
(Dhar & St Clair, 2009). However, another report has shown that in neuronal cells upon 
apoptotic stimuli, NPM translocates into the cytoplasm where it binds BAX and p53 
favouring mitochondrial cytochrome c release and apoptosis (Kerr et al, 2007). 
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NPM overexpression can also inhibit apoptosis in response to stress stimuli such as UV 
and hypoxia. NPM overexpression in NIH3T3 fibroblast leads to resistance to UV-induced 
apoptosis and increase of DNA repair through the inhibition of the IRF1 tumour 
suppressor, a transcription factor involved in DNA damage-induced apoptosis and cell 
cycle arrest (Kondo et al, 1997b; Wu & Yung, 2002). Moreover, NPM expression is 
induced after hypoxia, and human breast tumour cells overexpressing NPM are protected 
against hypoxic cell death. Indeed, it has been demonstrated that NPM inhibits p53 
phosphorylation on serine 15, which is essential for the activation of p53 in response to 
DNA damage, in response to UV irradiation and hypoxia (Li et al, 2004; Maiguel et al, 
2004). Thus, suggesting that hypoxia or UV driven cancer progression may require 
increased expression of NPM to suppress p53 activation and maintain cell survival. 
Although this data suggests that NPM acts as a negative regulator of the p53 tumour 
suppressor, some other observations have been published, reporting that NPM is involved 
in p53 stabilization and p53-dependent growth arrest (Colombo et al, 2002; Kurki et al, 
2004). Specifically, Colombo and colleagues have demonstrated that NPM interacts directly 
with p53, both in vitro and in vivo, and overexpression of NPM in primary diploid 
fibroblasts induces p53-dependent premature senescence, with concomitant redistribution 
of p53 to the nucleoli, where it is normally not present. NPM is also able to favour p53 
stabilization and activation in response to different kinds of stress and the loss of NPM 
protein impairs the p53-depedent cellular response to these stresses (Colombo et al, 2002). 
Similar data have been disclosed by Kurki and colleagues, who showed that depletion of 
NPM resulted in reduction of both stress-induced and basal levels of p53 (Kurki et al, 
2004). Based on these data, NPM could be relevant in the cellular response to radiation and 
genotoxic stress, through the activation of the p53 pathway. 
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Figure 3 - NPM overexpression in tumour cells leads to increased proliferation and inhibition of 
apoptosis. a. In normally proliferating tissues, NPM is expressed at physiological levels, and the balance 
between cell proliferation and apoptosis is maintained. b. In tumour cells, NPM is often overexpressed, and 
can exert its oncogenic potential both by stimulating cell proliferation and by inhibiting apoptosis. c. NPM 
overexpression can enhance cell growth and proliferation through the hyperactivation of ribosome 
biogenesis. NPM is also a target of the c-Myc transcription factor, whose alteration in tumours is often 
associated with deregulated protein synthesis. In addition, NPM is a putative stimulating factor for DNA 
synthesis and contributes to cell cycle progression. d. Overexpressed NPM prevents apoptosis through 
different mechanisms: it prevents the DNA-binding activity of IRF1, which normally induces differentiation 
and apoptosis, it binds and inhibits the eukaryotic initiation factor 2 kinase (PRK), it counteracts the DNA 
fragmentation activity of caspase-activated DNAse (CAD), it interacts and inhibits p53 response upon 
apoptotic stimuli. (From Grisendi et al, 2006).Numbers 1-12 represents positions of the exons. The lines in 
the scheme represent multiple alternative splicing events. Blue and yellow regions represent coding sequence 
and untranslated regions respectively (modified from Lim and Wang, 2006). 
 
4.1.2.4. NPM and maintenance of genomic stability  
NPM has been widely implicated in the control of genomic stability, both as putative 
regulator of chromosomal ploidy and as mediator of DNA integrity. Although the specific 
role for NPM at the centrosome is not fully elucidated, it has been shown that NPM binds 
centrosome and this association is regulated by different post-transcriptional modifications 
of the NPM protein during cell cycle (Jiang et al, 2000; Okuda et al, 2000), suggesting a 
possible role of NPM in controlling chromosome number. Concerning the role of NPM in 
the maintenance of DNA integrity, it has been shown that, after oncogene activation, NPM 
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overexpression strongly reduces the level of γ-H2AX, a surrogate marker of DNA damage, 
and the oncogene-dependent apoptosis or senescence is limited. Importantly, this effect 
was also confirmed in steady state condition, suggesting that the maintenance of DNA 
stability is a physiological function for NPM. Indeed, Npm-/- mouse embryos die in uterus 
at 10.5 dpc, display widespread apoptosis, p53 up-regulation and accumulation of γ-H2AX 
foci (Colombo et al, 2005). Importantly, these observations were also confirmed in Npm-
/- murine hematopoietic precursors derived from the yolk sac, where re-expression of 
NPM was sufficient to revert this phenotype (Colombo et al, 2005). Moreover, it has been 
demonstrated that Eµ-Myc transgenic mice show accelerated onset of B-cell lymphoma in 
an Npm1+/– genetic background. Furthermore, Npm+/– mice are much prone to the 
development of haematological malignancies late in life with respect to the wild type 
counterpart, suggesting that NPM acts as haploinsufficient tumour suppressor for 
haematopoietic disorders (Sportoletti et al, 2008). These data indicate an important role of 
NPM in the maintenance of DNA integrity although they do not permit to discriminate if 
the accumulation of DNA damage marked by γ-H2AX phosphorylation is due to direct 
involvement of NPM in the DNA repair machinery or constitutes an indirect effect of 
NPM activity on other pathways such as chromatin organization and DNA replication. 
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4.2.  NPM and haematopoietic malignancies 
Much of the interest in NPM biology has been bolstered by its involvement in human 
cancers, and in particular in haematopoietic malignancies. Undeniably, it is one of the most 
recurrently altered genes. Originally, NPM was studied as a partner of chromosomal 
translocations in various haematopoietic disorders, including anaplastic large-cell 
lymphoma (ALCL) with t(2;5) (Morris et al, 1994), the myelodysplasia-AML with t(3;5) 
(Yoneda-Kato et al, 1996) and cases of acute promyelocytic leukaemia (APL) t(5,17) 
(Redner et al, 1996). Translocations create chimeric genes encoding for fusion proteins 
(respectively NPM-ALK, NPM-MLF1, NPM-RARα) that form heterodimers with wild-
type NPM and promote cell transformation. 
Moreover, the region of the chromosome 5 to which the NPM1 gene maps is occasionally 
deleted in some cases of de novo myelodysplastic syndrome (MDS) and partial or complete 
loss of chromosome 5 is observed in therapy related MDS patients (Olney et al, 2002). 
However, the significance of NPM1 deletion in MDS remains to be elucidated. 
The most striking connection between NPM and haematopoietic malignancies comes from 
its involvement in acute myeloid leukaemia (AML) pathogenesis. 
AML represents a heterogeneous group of diseases characterized largely by bone marrow 
(BM) failure caused by accumulation of abnormal cells, referred to as blasts. From a 
morphological point of view, all AMLs are characterized by a blockage of normal 
haematopoiesis. The grade of blasts differentiation is used to divide the cases of AML in 8 
subgroups, M0 to M7, according to the French-American-British (FAB) classification. 
However, morphological criterion does not incorporate prognostically and therapeutically 
relevant information. Recent advances in the understanding of the vast genetic and 
epigenetic variability of AML have provided new insights with regards to the risk 
stratification of AML patients. In accordance, the newer World Health Organization 
(WHO)’s AML classification system integrates available genetic information in the attempt 
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at defining homogenous subgroups of prognostic and therapeutic relevance. The sub-
classification and prognostic prediction are first based on cytogenetic abnormalities found 
in approximately 50% of adult patients with AML. Generally, they are associated with poor 
or favourable prognosis depending on the underlying translocation (Estey, 2013). The 
remaining 50% of patients are cytogenetically normal and their prognosis is considered 
intermediate (Estey, 2013). In recent years, several efforts have allowed to identify 
mutations that permit further AML grouping, prognostic prediction, and potential 
development of targeted therapy. Following this challenge, in 2005, Falini and colleagues 
described mutations in the NPM1 gene associated to a large subgroup of adult NK-AML 
(Falini et al, 2005). More in detail, they reported an extensive study of 591 bone-marrow 
biopsy specimens from patients with primary AML analysed using immunohistochemistry 
to ascertain the subcellular localization of the NPM protein (Falini et al, 2005). The 
research samples included patients of different ages (15 to 60 years) and from all of the 
AML-FAB subtypes. Strikingly, in 35.2% of those specimens, NPM displayed an aberrant 
cytoplasmic staining (Figure 4), whereas, no NPM delocalization was observed in any of 
the 135 secondary AML cases analysed or in 980 haematological or extra-hematopoietic 
neoplasia other that AML (Falini et al, 2005). Due to the peculiar cytoplasmic 
delocalization of NPM, this subgroup of AML cases was denominated NPMc+AML (c+ 
indicates cytoplasmic positive) to distinguish from AML where NPM has the expected 
nucleolus-restricted expression. Finally, the authors demonstrated that mutations in the 
exon 12 of the NPM1 gene were predictive of the aberrant cytoplasmic localization of the 
protein making NPM one of the most frequently mutated genes in AML. 
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Figure 4 - NPM overexpression in tumour cells leads to increased proliferation and inhibition of 
apoptosis.  Subcellular patterns of expression of NPM in specimens from patients with AML using alkaline 
phosphatase anti-alkaline phosphatase (APAAP) staining method. In NPMc+AML (two left-hand panels), 
most leukaemic cells (arrow) show cytoplasmic NPM expression in addition to nuclear NPM expression; the 
arrowhead indicates a residual hematopoietic cell with the expected pattern of nucleus-restricted NPM. In 
NPMc+AML, nucleolin (C23) used as a positive control for the nucleolar localization is always restricted to 
the nucleus. In the two right-hand images, representative of NPMc- AML both NPM and nucleolin (C23) 
follow the same nucleus-restricted pattern with the exception of mitotic figures that show the expected 
cytoplasmic expression the two proteins. (Adapted from Falini et al, 2005). 	  
 
4.2.1. NPMc+ AML defines a distinct disease sub-group  
Several lines of evidence suggest that the NPM1 mutations are a founder genetic lesion in 
AML (Falini et al, 2011) and represent a distinct group of AML. The cytoplasmic pattern of 
localization is uniquely associated with de novo AML cases (Falini 2005; Liso et al, 2008), in 
which its frequency is as high as 50-60% of all newly diagnosed cases (Boissel et al, 2005; 
Falini et al, 2005; Thiede et al, 2006) and it is usually expressed in the whole leukaemic 
population (Falini et al, 2005). It has been only rarely found in myeloproliferative disorders 
(Caudill et al, 2006; Oki et al, 2006 ;Ernst et al, 2010) or myelodysplastic syndromes (MDS) 
(Zhang et al, 2007). Cytogenetic data indicate that NPMc+ staining closely correlates to 
normal karyotype (NK) (85%). Only a small percentage (15%) of cases bears minor 
chromosomal abnormalities (Falini et al., 2005) that most likely represent secondary events, 
since they are present only in a small percentage of blasts (Falini et al, 2005). Importantly, 
the presence of mutations in the NPM1 gene is mutually exclusive with other recurrent 
AML-associated genetic abnormalities such as t(15;17), t(8;21), t(6;9), inv(16) or 
rearrangements involving 11q23 (Schlenk et al, 2008). Moreover, NPMc+ detection is 
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stable during the course of the disease in patients (Meloni et al, 2009), likely representing a 
reliable marker for monitoring minimal residual disease (Schnittger et al, 2009). The 
hypothesis that NPMc+AML represents a distinct subgroup of AML is reinforced by the 
existence of specific biological characteristics associated with the disease of these patients. 
Morphological examination has shown multi-lineage involvement and NPMc+ staining was 
found in all FAB subgroups with the exception of M3 (acute promyelocytic leukaemia), 
M4eo (acute myelomonocytic leukaemia with eosinophilia) and M7 (acute megakaryocytic 
leukaemia) (Falini et al., 2005; Pasqualucci et al, 2006). The multilineage involvement 
correlated with the negativity of the CD34 antigen (Falini et al, 2005; Taussig et al, 2010) 
suggesting that NPMc+AML derived from either a common myeloid or an earlier 
progenitor. However, it has been recently shown that a rare CD34+ population purified 
from patients’ blasts can engraft in immunocompromised mice and support the 
development of leukaemia that recapitulates the original disease. 
Moreover, gene expression profile studies have identified a specific signature, intriguingly, 
characterized by an up-regulation of homeo-box genes and other genes involved in the 
stem-cell maintenance (Alcalay et al, 2005). 
An additional indication suggesting that NPMc+ AML may represent a distinct group of 
AML is the peculiar correlation with another frequent genetic abnormality found in AML: 
FLT3-ITD (internal tandem duplication of fms-related tyrosine kinase 3 gene) (Falini 
2005). This mutation is present twice as frequently in cases of NPMc+ AMLs as compared 
to the cases of NPMc- AML. NPM1 mutations likely precede the appearance of FLT3-
ITD, since FLT3-ITD is lost at relapse in approximately 9% of cases (Falini et al, 2011) 
further suggesting that NPMc+ mutations are a primary genetic event. Interestingly, while 
NPMc+ AML patients are characterized by good prognosis due to higher remission rate 
after chemotherapy, the co-presence of FLT3-ITD mutation is associated with poor 
prognosis (Dohner 2005). In accordance with all these observations, NPMc+AML has 
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been included as a provisional entity in the 2008 World Health Organization (WHO) 
classification of lymphoid and hematopoietic neoplasia. 
 
4.2.2. Mutations are located in the exon 12 of the NPM1 gene 
From a genetic point of view, mutations in NPM1 gene are heterogeneous (Falini et al, 
2007), with more than 40 mutations reported to date. Beside the molecular variability, 
NPM1 mutations share crucial common features. Virtually all of them are restricted to the 
exon 12 of the gene, with only two exceptions described involving the splicing donor site 
of NPM1 exon 9 (Mariano et al, 2006) and exon 11 (Albiero et al, 2007). Every mutation 
generates a shift in the reading frame that alters the C-terminal domain of the protein 
abrogating at least one of the two tryptophans that are important for nucleolar localization 
(W288 and W290) (Falini et al, 2006; Mariano et al, 2006) (Figure 5). Notably, NPM 
mutants not only loose the nucleolar localization signal (WXW), but they also gain a novel 
leucine-rich nuclear export signal (NES), which is recognised by the CRM1-dependent 
export machinery responsible for the NPM nuclear export (Yu et al, 2006). The presence 
of this additional NES is responsible for the cytoplasmic localization of the mutant protein 
(Mariano et al, 2006). However, despite the variability of mutations described, one 
mutation, the so called Mutation A, that consists in a duplication of a TCTG 
tetranucleotide at position 956-959 of the sequence (Gen Bank accession number 
NM_002520), accounts for about 75-80% of incidence. 
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Figure 5 - Mutations in the exon 12 of the NPM1 gene and in the encoded protein.  
The wild-type NPM sequence (nucleotides 952 through 989) is aligned with six mutant variants, called A to F. 
Red font indicates nucleotide insertion. The predicted protein is always shown, with boxed area indicating the 
positions of two C-terminal tryptophan (W) residues; the wild type tryptophan residue is shown in yellow, 
and the mutated residues are in grey. The new amino-acid sequence common to all of the mutated proteins is 
shown in green. (Adapted from Falini et al, 2005).Numbers 1-12 represents positions of the exons. The lines 
in the scheme represent multiple alternative splicing events. Blue and yellow regions represent coding 
sequence and untranslated regions respectively (modified from Lim and Wang, 2006). 
 
4.2.3. NPMc+ and its putative oncogenic pathways 
Different molecular mechanisms have been proposed to explain the transforming 
proprieties of the NPMc+ mutants. Available data suggest that the key event is a domino 
effect unleashed by the delocalization to the cytoplasm of several NPM interacting 
partners. An intriguing scenario depicts the mutated protein affecting both a crucial tumour 
suppressor pathway (Arf-p53) (Colombo et al, 2005) and the stability of a potent cellular 
oncogene as c-MYC (Bonetti et al, 2008) (Figure 5). Indeed, it has been shown that NPM is 
required for the nucleolar localization and stability of both ARF and Fbw7γ, a regulator of 
c-MYC stability (Figure 6). 
NPM and ARF. ARF, p19Arf in mouse or p14Arf in human, is a crucial tumour 
suppressor involved in cell cycle arrest and apoptosis in response to oncogenic stimuli, 
mainly through the inhibition of MDM2-mediated regulation of p53. MDM2 functions as 
E3 ligase, which ubiquitinates p53, and is critical for the export of p53 from the nucleus to 
the cytoplasm, where p53 is degraded (Boyd et al, 2000; Geyer et al, 2000). It was originally 
proposed that ARF sequesters Mdm2 in the nucleolus where it cannot bind and 
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ubiquitinate p53 (Weber et al., 1999). NPM associates with ARF in high-molecular weight 
complexes within the nucleolus (Bertwistle et al, 2004) and stabilizes ARF by retarding its 
turnover. In leukemic cells, NPMc+ retains the ability to interact with ARF and causes its 
cytoplasmic delocalization, which in turn affects its normal function. NPMc+ limits the 
ability of ARF to induce sumoylation of MDM2, and attenuates the ARF-dependent 
activation of the p53 transcriptional programme (den Besten et al, 2005). Therefore, 
leukaemia that carry a mutated NPM allele might be characterized by functional 
inactivation of the ARF tumour-suppressor pathway. 
NPM and c-MYC regulation. Fbw7γ is a component of the E3 ligase complex 
responsible for the proteasome degradation of c-Myc (Yada et al, 2004;(Popov et al, 2007; 
Yada et al, 2004). In the presence of the NPMc+, Fbw7γ is delocalized into the cytoplasm 
where it is degraded; as consequence, c-Myc is stabilized (Bonetti et al, 2008). It has been 
shown that c-Myc overexpression in normal cells promotes an aberrant cellular 
proliferation leading to the activation of a p53-Arf dependent checkpoint, whose function 
is to limit proliferation and eventually transformation (Dominguez-Sola et al, 2007). 
However, in NPMc+ expressing cells the p53/ARF checkpoint is impaired because ARF is 
delocalized and degraded thus favouring the proliferation and the transformation process 
(Colombo et al, 2005). Hence, a single genetic mutation in the NPM locus may have the 
double effect of activating proliferation and attenuating the resulting checkpoint response. 
However, these data are based on in vitro observations and, consequently, represent an 
excessive simplification considering the complexity of cellular activities in which NPM is 
involved and the specificity of the environment in which NPM exert its oncogenic activity. 
Therefore, an accurate study of the NPMc+ transforming proprieties requires the 
availability of a mouse model in which NPMc+ is specifically express in the 
haematopoietic. 
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Figure 6 - NPMc+ protein attenuates an oncosuppressor pathway and enhances an oncogenic one. 
Normal cells: NPM is mainly localized in the nucleolus and is required for nucleolar accumulation and 
stability of FBW7g and ARF. This is relevant for the control of MYC turnover and provides an active pool of 
ARF ready to inactivate the HDM2-mediated p53 degradation in response to cellular stress. AML blast: the 
mutant NPM protein (NPMmut) is mainly localized to the cytoplasm and causes cytoplasmic delocalization 
and degradation of ARF and FBW7γ. As a consequence, HDM2 can induce ubiquitination/degradation of 
p53, and MYC accumulates and activates its target genes (from Di Fiore, 2008). 
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4.3.  Acute Myeloid Leukaemia pathogenesis 
4.3.1. AML as a multistep process  
The fundamental features of AML include inappropriate proliferation, acquired self-
renewal potential, escape from programmed cell death, block of differentiation and multi-
organ dissemination of leukemic cells. Different lines of evidence support a multistep 
process AML pathogenesis. First, data from murine models indicate that expression of a 
single mutated gene is not sufficient to cause AML. For instance, it has been shown that 
the RUNX1-CBFA2T1 or CBFB-MYH11 fusion genes, resulting from the t(8;21), and 
inv(16)/t(16;6), respectively, can block myeloid differentiation but are not able to cause 
frank leukaemia (Castilla et al, 1999; Kelly et al, 2002b; Licht, 2001). Whereas, constitutively 
activated signalling molecules, such as FLT3 or RAS family member, induce a 
myeloproliferative phenotype (Kelly et al, 2002; Chan et al, 2004). Furthermore, study in 
mice directly demonstrated cooperation between different mutations (Kelly et al, 2002a; 
Schessl et al, 2005; Wang et al, 2011). Moreover, mutational analysis of AML has 
demonstrated that many patients have more than one recurrent genetic abnormality 
(Ishikawa et al, 2009). In accordance to these pieces of evidence, the Knudson “two-hit” 
model of tumourigenesis (Kosmider & Moreau-Gachelin, 2006) proposed that at least two 
genetic events must take place for a tumour to develop. Thus, it has been suggested that 
genetic alterations associated with AML can be classified into two complementary 
functional categories. The class I mutations increase cellular proliferation and survival, 
typically by constitutive activation of tyrosine kinase signalling pathways, such as mutations 
in the FLT3 gene. By contrast, the class II mutations result in a block of normal 
hematopoietic cell differentiation and/or aberrant self-renewal potential and frequently 
involve transcriptional regulators of normal hematopoietic differentiation. Murine model 
bearing class I mutation usually do not develop leukaemia, in contrast to class II mutation. 
This second group of mutations shows leukaemia initiating potential in mouse, but, 
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notably, often only following a long period of latency. It has been suggested that during 
this period a class I mutation is selected and cooperate to give rise to the tumour 
phenotype. NPMc+ mutations have been proposed to belong to the second class of 
mutations (Ishikawa et al, 2009). 
 
4.3.2. AML associated mutations 
Evidence of the genetic basis of AML initially came from cloning of recurring 
chromosomal translocations breakpoints associated with malignant phenotypes. 
Chromosomal translocations are detected in approximately 60-50% of adult AML, and pre-
treatment karyotype has long been recognized as the most important independent 
predictor of clinical outcome (Mrozek et al, 2004). However, 40-50% of AML patients are 
associated to a normal karyotype and their risk stratification is very heterogeneous (Estey & 
Dohner, 2006; Lowenberg et al, 2003). The progress in the high throughput sequencing 
methods has provided the tools for alternative approaches to the identification of disease 
alleles in NK-AML. Importantly, it has demonstrated the beyond cytogenetic risk 
classification, molecular genetic markers are clinically significant factors in the response to 
therapy and survival (Schlenk et al, 2008). ). Somatic mutations in AML include partial 
tandem duplication (PTDs) of the myeloid–lymphoid or mixed-lineage leukaemia gene 
(MLL) (Caligiuri et al, 1994), internal tandem duplications (ITD) (Nakao et al, 1996) or 
mutations of the tyrosine kinase domain (TKD) (Yamamoto et al, 2001) of the fms-related 
tyrosine kinase 3 gene (FLT3), and mutation in the nucleophosmin gene (NPM1) (Falini et 
al, 2005), the CCAAT/enhancer binding protein α gene (CEBPA) (Pabst et al, 2001), and 
the neuroblastoma RAS viral oncogene homolog gene (NRAS) (Bos et al, 1985). 
In particular, Flt3 mutations show important association to prognostic factor and will be 
discussed in more detail as the presence of Flt3 mutation in patients with NPMc+AML 
drastically worsens the prognosis. 
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FLT3 mutations. The FMS-like tyrosine kinase 3 (FLT3) gene encodes a class III 
receptor tyrosine kinase (RTK) (Rosnet et al, 1993). FLT3 plays a critical role in normal 
haematopoiesis (Gilliland & Griffin, 2002) and within the hematopoietic system, its 
expression occurs primarily in immature myeloid and lymphoid progenitors. Targeted 
disruption of FLT3 gene results in healthy adult mice with normal mature hematopoietic 
populations, however, these animals demonstrate deficiencies in primitive pro-B and pre-B 
cell lymphoid compartments (Mackarehtschian et al, 1995). These data indicate an 
important role for FLT3 in the development of multipotent hematopoietic and lymphoid 
cells. High level of wild-type FLT3 expression has been associated with different 
haematological malignancies including the vast majority of patients with AML (70-90%) 
and a large proportion of B cell acute lymphoblastic leukaemia (B-ALL). Different types of 
mutations affect the FLT3 gene. Internal tandem duplications (ITD) within the 
juxtramembrane (JM) domain of FLT3 occur in approximately 25% of AML patients, 
making it one of the most frequent alterations in adult AML (Frohling et al, 2002). FLT3-
ITD mutations result in a ligand-independent receptor dimerization, constitutive FLT3 
signalling, and activation of the STAT5, RAS/MAPK, and PIK pathways. Another major 
class of FLT3 mutations that also cause constitutive FLT3 activation involves the 
activation loop (AL) of the second kinase domain (Yamamoto et al, 2001) and it is detected 
in approximately 5%–10% of AML patients. Lastly, a group of point mutations within the 
JM domain have also recently been described in approximately 1% of AML (Reindl et al, 
2006). Gain of function mutation in FLT3 gene, in particular FLT3-ITD mutations, is of 
significant clinical consequence. In fact numerous studies have shown that FLT3-ITD 
mutations may be associated with disease progression, increased risk of relapse and shorter 
overall survival (Frohling et al, 2002). Furthermore, patients with low or absent levels of 
wild-type (WT) FLT3, consistent with homozygosity for the FLT3-ITD allele, appear to 
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have a particularly dismal outcome, suggesting FLT3-ITD gene dosage has biologic and 
prognostic significance. 
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4.4.  Haematopoietic stem cells and cancer stem cells 
4.4.1. Haematopoietic stem cells (HSC) 
Haematopoiesis is the lifelong process by which all cells in the blood are produced in a 
hierarchical fashion starting from a rare population of multi-potent haematopoietic stem 
cells (HSC), which are located in bone marrow. Stem cells are cells with a unique fate, as 
they are clonal precursors of both other stem cells of the same type (self-renewing 
potential) as well as a defined set of differentiated progeny (differentiating potential) 
(Weissman, 2000). In accordance, HSCs give rise to progenitor cells that become 
increasingly lineage restricted and eventually differentiate into all lineages of mature blood 
cells. However, as HSCs continually replenish cells that turned over, they must self-renew 
to maintain themselves over the lifetime of the organisms. A complex network of cell 
intrinsic and extrinsic pathways, whose function is to maintain a homeostatic balance 
between HSC self-renewal and life-long replenishment of lost blood cells, tightly regulates 
this process. 
So far, HSC are probably the best characterized adult stem cell population with respect to 
cell surface markers for purification and availability of assays to test functional potential. In 
1961, the pioneering work of Till and McCulloch, for the first time, formally demonstrated 
the existence of rare cells in the mouse bone marrow able to form myeloerythroid colonies 
in the spleens of irradiated mice transplants (Till & Mc, 1961). These clonogenic 
population gave rise to same cells that could also be retransplanted to secondary hosts and 
there reconstitute all blood cell lineages (Becker et al, 1963); (Siminovitch et al, 1963); (Wu 
et al, 1968). These findings paved the way to the eventual purification of mouse HSC by 
prospective isolation using fluorescence-activated cell sorting (FACS) with the use of 
combinations of monoclonal antibody cell surface determinants (Spangrude et al, 1988); 
(Osawa et al, 1996) or vital dye staining (Goodell et al, 1996). Over the last 20 years, the 
prospective isolation of HSC has challenged the field with the continual reporting of new 
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markers for HSC purification improving the purification strategy to yield the highest 
proportion of HSC (Kiel et al, 2008; Wilson et al, 2008). Therefore, since the discovery of 
functional HSC, extensive investigations using limiting dilution up to single-cell 
transplantation assays in combination with the use of unique cell surface markers profile 
have allowed for the isolation of at least two classes of multi-potent cells with long term 
(LT-HSCs) and short term (ST-HSCs) reconstitutive potential (Morrison & Weissman, 
1994) (Figure 7). The long-term subset self-renews for all the life of the host, while the 
sort-term subset maintains self-renewal capacity for approximately 8 weeks (Morrison & 
Weissman, 1994). Understanding the cellular hierarchy of haematopoietic system was then 
next achieved. At the top of the hierarchy are placed HSCs that self-renew for all the life 
are placed. These cells progress to multipotent progenitor cells (MPP), an intermediated 
progenitor stage that commits to one of the two oligolineage-restricted cells: the common 
lymphocyte progenitors (CLPs) and the common myeloid progenitors (CMP). CLPs are 
restricted to give rise to T- lymphocytes, B-lymphocytes and natural killer (NK) cells 
(Kondo et al, 1997a) whereas CMPs are progenitors for the myeloerythroid lineage (Akashi 
et al, 1999). Then CMP give rise to megakaryocyte-erythrocytes progenitors (MEPs) and 
granulocyte-macrophage progenitors (GMPs) (Akashi et al, 1999). Finally, these 
progenitors provide all of the lineage-committed effector cells of the blood system. In 
normal circumstances, each stage of differentiation of multipotent cells involves 
functionally irreversible maturation steps and no dedifferentiation or trans-differentiation is 
permitted between haemato-lymphoid progenitors. 
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Figure 7 - The hierarchy of the haematopoietic cells. 
 LT-HSC, long term repopulating HSC; ST-HSC, short-term repopulating HSC; MPP, multipotent 
progenitor; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; MEP, 
megakaryocyte/erythroid progenitor; GMP, granulocyte-macrophage progenitor. The encircled pluripotent 
population, LT-HSC, ST-HSC, and MPP are Lin-, Sca+, c-Kit+, as shown.	  
 
 
4.4.2. Cancer stem cells (CSC) 
The classical multi-step model of tumourigenesis requires a long-lived cell in which 
multiple genetic hits can occur and be propagated (Vogelstein et al, 1988). In accordance, 
investigators postulated that candidate target cell for tumour initiation could be a stem cell. 
Similarily to a normal stem cell, the cancer stem cell (CSC) must have self-renewal potential 
to maintain the tumour, and differentiating/proliferating capability to fuel the tumour bulk 
(Figure 8). The existence of CSC and hierarchical organization within tumour population is 
also suggested by clinical data. In many cancers, standard chemotherapy can induce 
elimination of tumour bulk and disease remission in patients. Unfortunately, a high 
percentage of those patients will relapse even after a long time (Peloquin et al, 2013; Sorror 
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& Appelbaum, 2013). This evidence suggests biological heterogeneity within tumour cells 
(Fidler, 2012). Whereas cells that are efficiently eliminated by therapy compose tumour 
balk, the cancer-initiating cells, namely CSCs, escape normal chemotherapy based on their 
different biology (Jordan et al, 2006). 
The first formal demonstration of a rare population of cancer-initiating cells came from 
studies performed on AML patients. In 1994, Dick and colleagues identified a rare 
subpopulation of cancer cells able to initiate disease in immune-deficient mice (Lapidot et 
al, 1994). These cells showed differentiating and self-renewing abilities, as they were able to 
form tumours with the same cell heterogeneity of the tumour of origin, and could be 
serially transplanted to obtain tertiary tumours. In addition, the surface markers that 
prospectively identified the AML-initiating cells were found to be specifically expressed in 
the corresponding normal SCs, as they were CD34+/CD38-. This finding strongly 
supports the cancer stem cell model, in which a unique rare population, with stem cell 
characteristics, could support tumour development. Because these AML-initiating cells 
represented less than the 0.01% of the total leukaemia cells, the authors concluded that rare 
cells in tumours share the same features as normal SCs and can be referred to as cancer 
stem cell (CSCs) (Campbell and Polyak, 2007; Visvader and Lindeman, 2008). 
Since the first identification in AML, CSCs have been identified in other tumours, 
including brain and breast cancer (Kai et al, 2010; Singh et al, 2003). Developing new 
therapeutic strategies that specifically target CSC represents a promising option for the 
treatment of cancer. However, this goal requires, as an essential prerequisite, a profound 
understanding of the normal pathways perturbed by oncogene activation, as well as 
knowledge of the aberrant mechanisms that support the establishment of the clonal 
dominance during malignant evolution.  To this end, the development of proper mouse 
models that represent a formidable platform to investigate how the transition from a 
normal to malignant stem cell is necessary. 
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Figure 8 - Stem cell system.  
 Normal tissues arise from a central stem cell that grows and differentiates to create progenitor and mature 
cell populations. Key proprieties of normal stem cells are the ability to self-renew (indicated by curved arrow), 
multilineage-differentiation potential (indicated by cells with different colours) and extensive proliferative 
capacity. Cancer stem cells arise by means of a mutation in normal stem cells or progenitor cells, and 
subsequently grow and differentiate to create primary tumours (the broken arrow indicates that specific types 
of progenitors involved in the generation of cancer stem cells are unclear). Like normal stem cells, cancer 
stem cells can self-renew, give rise to heterogeneous populations of daughter cells, and proliferate extensively 
(from Jordan, 2006).	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5.1 Animal manipulation 
5.1.1 Animal models 
NPMc+ mice were described in Results Section, paragraph 6.1.1. FLT3-ITD mice were a 
kind gift of Prof. Gilliland and were previously described (Lee, 2007). Cre-ER-TM mice 
and EFYP mice were previously described 	  (Hayashi, 2002) (Srinivas, 2001). C57BL/6 and 
C57BL/6-Ly5.1 animals were purchased from Charles River. 
All animals were kept under specific pathogen free conditions. Mouse experimentations 
were performed under the protocol number approved by the Italian Ministry of Health. 
5.1.2 Histology 
Tissue samples were fixed in PBS1X 4% formalin and embedded in paraffin. Haematoxylin 
and Eosin (H&E) staining were performed according to the following standard protocol. 
5 µm sections of bone marrow, spleen, liver, were deparaffinized and hydrated to water, 
stained with hematoxylin (cat. numb. 03972, Fulka) for 5 minutes, washed in running tap 
water for 5 minutes, counterstained with eosin (cat. numb. 03972, Fulka) for 3 minutes, 
dehydrated in 95% and absolute alcohols and mounted. 
5.1.3 Cytology 
Peripheral blood smear were analyzed using standard May-Grunwald–Giemsa staining 
protocol. Slide were fixed in methanol 15 minutes, stained in May-Grunwald (MG1L, 
Sigma) solution for 5 minutes, and then stained in Giemsa (GS500, Sigma) for 10 minutes. 
At the end samples were rinsed and mounted in histolemon. 
5.1.4 Bone marrow transplantation (BMT) 
5 million of BM-MNC cells were transplanted in 6.5 Gy irradiated CD45.1 syngenic mice 
for leukemiogenic study. 
For competitive BMT, 1 million of test BM-MNC along with 1 million of competitive BM-
MNC were transplanted in 7.5 Gy irradiated CD45.1 syngenic mice. 
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For serial BMT, 2 million of BM-MNCs were transplanted in 7.5 Gy irradiated CD45.1 
syngenic mice. 
5.1.5 5-Fluorouracil (5-FU) treatment 
5-FU was administrated at dosage of 150 mg/kg by intraperitoneal injection every 7 days 
until mice death. 
5.1.6 5-Bromo-2-deoxyuridine (BrdU) in v ivo  administration  
BrdU (BD.pharmngen) was administrated by intraperitoneal injection (1 mg/mouse) at 
repeated doses every 6 hours. 
5.1.7 In vivo  tamoxifen treatment 
Mice were intraperitoneatelly-injected wit 1 mg of tamoxifen (Sigma) 10 times. 
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5.2 Molecular Biology Techniques 
5.2.1 Genomic DNA extraction from tail biopsy 
Mouse tissue or cells were lysed o/n at 56°C in 400 ml lysis buffer (100 mM Tris-HCl pH 
8; 5 mM EDTA; 200 mM NaCl; 0.2% SDS; 100mg/ml Proteinase K), shaking at 850 rpm, 
overnight in Thermomixer compact. Undissolved debris were pelleted and DNA in the 
supernatant was precipitated with 1 ml of isopropanol. The DNA was pelleted by 
centrifugation, air-dried and resuspended in 400 µl of milliQ water by incubation at 50˚C 
for 20 min. 
5.2.2 Genotyping strategy 
The genotypes of all mice offsprings were analyzed by polymerase chain reaction (PCR) 
performed on genomic DNA extracted from tail. For amplification, primers summarized in 
Table A and PCR reagents in Table B were used. PCR conditions are summarized in Table 
C/D. PCRs were run in automatic thermocycler GeneAmp PCR System9700 (Applied 
Biosystems). 
5.2.3 Agarose gel electrophoresis and DNA gel extraction 
Separation of DNA fragments by size was achieved by electrophoresis in agarose gels 
(0.7% - 2.5%; 1x TAE (Sambrook & Russell, 2001); 1x GelRedTM, BIOTIUM). As a size 
marker for agarose gel electrophoresis 1kb plus ladder (NEB, USA) was used. 
5.2.4 RNA and DNA extraction  
Total RNA was extracted from 106 cells, using QIAGEN RNeasy kit following the 
manufacturer’s protocol. A DNAse (QIAGEN) digestion step was added before elution to 
ensure the complete elimination of contaminant DNA.  
5.2.5 cDNA synthesis  
Complementary DNA (cDNA) was produced using SuperScript® VILO™ cDNA 
Synthesis Kit (Invitrogen) following the manufacturer’s protocol. Specifically, master mix 
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(containing 5X VILOTM Reaction Mix, 10X SuperScript® Enzyme Mix, water and RNA) 
was incubated for 10 min at RT. For increased yields of cDNA incubation time was 
prolonged to 120 min at 42°C. Reaction was terminated by 5 min incubation at 85°C. 25 ng 
of cDNA were used for real time PCR reaction. 
5.2.6 Real-time quantitative PCR (RT-qPCR) 
For gene expression analysis RT-QPCR was performed using 25 ng of cDNA, 500 nM 
primers mix and 10 µl of LightCycler 480 SYBR Green I Master, containing Hot-start 
polymerase (Roche) in a final volume of 20 µl per reaction in 96-well format. Reaction 
conditions were: 95°C for 10 min, 45 cycles of 95°C for 1 sec, 60°C for 10 sec, 72°C for 1 
sec. Accumulation of fluorescent products was monitored using a LightCycler® 480 Real-
Time PCR System (Roche). Specificity of PCR reaction was controlled by the melting-
temperature profiles of final products (dissociation curve). Ribosomal protein large p0 
(Rplp0) gene was used as a control housekeeping gene for normalization (Akamine et al, 
2007; Laborda, 1991). Primers are listed in Table E.  	  
Table A: Genotyping primers, annealing temperatures and amplicons 
Primers  TA Product 
NPMc+   Amplicon size 
5’-TGCTTCAGTCCCATGTTTGGCAAGG-3’ NPMc+ Fw 
65°C 
Tg 800 bp 
5’-AAATCTGTGCGGAGCCGAAATCTGG-3’ NPMc+ Rv   
FLT3-ITD     
5’-AGGTACGAGAGTCAGCTGCAGATG-3’ FLT3_ITD Fw 60°C Wt 200 bp 
5’-GATCATGAACAAAGTCACTGTAAATG-3’ FLT3_ITD  rv  Tg 240 bp 
eYFP     
5’-GCCATGCCCGAAGGCTACGTCC-3’ YFP Fw 60°C Tg 280 bp 
5’-AGCTGCACGCTGCCGTCCTCGATG-3’ YFP Rv    
CRE-ER-TM     
5’-ACGAACCAAGGTGACAGCAATG-3’ CRE Fw 58°C Wt 250 bp 
5’-CTCGACCAGTTTAGTTACCC-3’ CRE Rv    
HPRT     
5’–TGTGTGTGTGTGTGTGTAGGTCACC-3’ HPRT Fw 60°C Wt 800bp 
5’-GGTTGCTGGAGTGCTTGCC-3’ HPRT Rv    
 
                                                                                        MATERIALS AND METHODS 
34	  
Table B: Master mix used for PCR genotype 
PCR master mix µl 
H2O 15.3 
10x CoralLoad PCR buffer (contains 15mM MgCl2) 2.5 
5x Q solution 5 
dNTPs 10 mM 0.5 
primer Fw 100 µM 0.25 
primer Rv 100 µM 0.25 
Taq DNA Polymerase 0.2 
DNA 1 
Total 25 
 
Table C: PCR condition for genotype (CRE-ER-TM, FLT3-ITD, HPRT, YFP) 
 
 
 
 
X 35 
	  
Table D: Condition used for PCR genotype (NPMc+) 
 
 
 
X 35 
 
 
 
 
 
 
 
PCR cycle  
Temperature (°C) Time (min) 
95 5 
94 0:30 
TA 0:30 
72 0:30 
72 7:00 
4 Hold 
PCR cycle  
Temperature (°C) Time (min) 
95 5:00 
94 0:30 
65 0:30 
68 5:00 
72 8:00 
4 Hold 
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Table E: Primer sequences for quantitative PCR analyses 
Primers Sequence Target 
HOXA5 Fw 
CGCAAGCTGCACATTAGTCA 
RNA 
HOXA5 Rv CATCCTCCTGTTTTGGAACC RNA 
HOXA7 Fw GCCTCCTACGACCAAAACAT RNA 
HOXA7 Rw CTTCTCCAGTTCCAGCGTCT RNA 
HOXA9 Fw ATGCTTGTGGTTCTCCTCCA RNA 
HOXA9 Rw CTTCTCCAGTTCCAGCGTCT RNA 
HOXA10 Fw CAGCCCCTTCAGAAAACAGT RNA 
HOXA10 Rw CGCTACGGCTGATCTCTAGG RNA 
HOXB6 Fw CCGCATAGCCAGACGAGTAGA RNA 
HOXB6 Rw TTCCTATTTCGTGAACTCCACCTT RNA 
TATA box Protein 
(TBP) Fw CTGGAATTGTACCGCAGCTT  
RNA 
TATA box Protein 
(TBP) Rw 
 
TCCTGTGCACACCATTTTTC 
 
RNA 
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5.3 Cell Culture 
5.3.1 Preparation of BM-MNCs and spleen cell suspension  
Single-cell suspensions were obtained by grinding bone marrow or spleen by crashing 
followed by filtering through 70 mm nylon meshes (Becton Dickinson, USA). 
BM-MNCs were layered onto density gradient (HISTOPAQUE 1083, SIGMA –
ALDRICH) upon centrifugation at 14C at 1500 rpm for 35 minutes. During centrifugation, 
erythrocytes are aggregated by polysucrose and rapidly sediment; whereas, lymphocytes and 
other mononuclear cells remain at the plasma-HISTOPAQUE interface.  
 Erythrocytes lyses from peripheral blood was achieved incubating cell suspensions in 1 ml 
of a 9:1 (v/v) solution of 0.15M NH4Cl and 0.17M Tris-HCl pH 7.65 for 3 min on ice. 
Cells were centrifuged at 1200 rounds per minute (rpm) at 4°C and. 
Live cells were counted using Trypan blue dye to distinguish live and dead cells. 
5.3.2 Colony-forming unit  (CFU) assay 
Myeloid colony-plating assays were performed in methylcellulose- based medium (M3434) 
containing 3 U/ml erythropoietin, 10 ng/ml recombinant murine interleukin-3 (rmIL-3), 
10 ng/ml rmIL-6, and 50 ng/ml rmSCF (Stem Cell Technologies, Vancouver, BC, 
Canada). For primary methylcellulose cultures, cells were seeded in triplicate and scored for 
colony formation 7–10 days later. Serial replating was carried out as previously described 
(Lee, 2007) in three independent experiments with 104 cells replated in duplicate for each 
round of replating and colony counts performed on 7-10 days. 
5.3.3 TAT-Cre transduction of BM-MNCs 
BM-MNCs were washed three times, re-suspended in serum-free media (Hyclone, USA) at 
a density of 5x106 cells/ml and incubated for 45 min at 37°C with 100 µg/ml (final 
concentration) of recombinant TAT-Cre. Transduction was stopped diluting samples with 
10 volumes of BM-MNCs medium (IMDM (Gibco/Invitrogen, Carlsbad, CA) plus 12.5% 
heat inactivated fetal bovine serum (FBS), 12.5% Horse serum, 1% L-glutamine, 
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100ng/mL SCF, 20ng/mL IL3, and 20ng/mL IL6 (Pepro Tech, Rocky Hill, NJ), 0.1% β-
mercaptoethanol, and Hydrocortisone 10ng/mL.), cells were spun down, re-suspended in 
BM-MNCs medium and cultured at a density of 2 x 106 cells/ml. Deletion efficiency was 
evaluated 24-48 hours later by flow cytometry. 
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5.4 Imaging analysis 
5.4.1 Flow cytometry and cell sorting analysis 
For flow cytometric analysis aliquots of 1x106 cells were stained for 30 minutes on ice in 
100 µl FACS buffer (1% PBS, 1% BSA, 0.01% Sodium Azide (N3) containing the 
appropriate mixture of fluorescently labeled antibodies (Abs). Two-step staining was 
performed when biotinylated Abs were detected using fluorescently-labeled streptavidin as 
secondary reagent. Stained cells resuspendend in FACS buffer were acquired on a 
FACSCalibur (BD Pharmingen, USA) and data were analyzed using Flowjo software (Tree 
Star, USA). Dead cells were excluded from the analysis based on forward and side scatter 
parameters. Sorting of labeled cells was performed with a FACS Vantage or FACS Aria 
(BD Pharmingen, USA). Monoclonal Abs were purchased from eBioscience.  
List of Abs as well as working dilutions are listed in Table F. Lineage negative cell (Lin- 
cell) were identified according to the low expression of MAC1; Gr1; B220; CD3; Ter119. 
LT-HSC were identified according to the following immunophenotype (Lin-; SCA+; 
cKit+; CD34-; FLK-). ST-HSC were identified according to the following 
immunophenotype (Lin-; SCA+; cKit+; CD34+; FLK-). MPP were identified according to 
the following immunophenotype (Lin-; SCA+; cKit+; CD34+; FLK+). 
 
Table F: List of antibodies used for flow cytometry 
Antibodies and antigen (clone) Source Dilution factor 
Monoclonal Rat–anti rat mac (clone M1/70) eBiosciences 1/200 
Monoclonal Rat–anti rat GR1 (clone RB6-8C5) Home-made 1/200 
Monoclonal Rat–anti ratB220 (clone RA3-6B2) Home-made 1/200 
Monoclonal Rat–anti rat CD3 (clone 145-2C11) eBiosciences 1/200 
Monoclonal Rat–anti rat ter119 (clone TER-119) eBiosciences 1/200 
Monoclonal Rat–anti rat Sca-1 (clone E13-161.7 ) eBiosciences 1/100 
Monoclonal Rat–anti rat ckit (clone 2B8) eBiosciences 1/100 
Monoclonal Rat–anti rat CD34 (clone RAM34 ) eBiosciences 1/100 
Monoclonal Rat–anti rat FLK (clone A2F10) eBiosciences 1/100 
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5.4.2 Cell cycle analysis 
 Surface stained cells were fixed in BD Cytofix/Cytoperm™ buffer for 20 min at room 
temperature (RT), washed by Perm/Wash™ Buffer (P/W) and re-fixed in BD 
Cytofix/Cytoperm™ Plus buffer for 10 minutes, at RT, light protected. Cells were washed 
with P/W and incubated 5 minutes with BD Cytofix/Cytoperm™ buffer, at RT, light 
protected, and washed again with P/W. Fixed cells were treated with 300 mg/ml DNAse 
for at least 1 hour, at 37°C, washed with P/W, and stained with anti-BrdU-APC (BD 
Pharmingen, Cat: 51-23619L) conjugated antibody, 30 minutes, RT. Stained cells were 
washed two times, re-suspended in 1 ml of cold PBS containing hoacst (50 µg/ml, Sigma), 
and incubated overnight at 4°C. Samples were acquired by FACS-ARIA (BD) and analyzed 
using FlowJo software. 
5.4.3 Immunofluorescence 
Cells were fixed in suspension with 4% paraformaldehyde for 10 minutes, washed three 
times in PBS1X and plated onto polilysinated coverslips. Cells were then permeabilized 5 
minutes with 0.1% Triton-X100 in PBS at room temperature, washed three times in PBS 
and blocked with 3% BSA in PBS (blocking solution) for 20 minutes. Staining with primary 
antibodies was performed in a humid chamber for 1 hour at room temperature and 
followed by three washes in PBS1X. Coverslips were then stained with secondary 
antibodies for 30 minutes at room temperature, washed three times in PBS1X, 
counterstained with DAPI and mounted in mowiol. Samples were analysed under an AX-
70 Provis (Olympus) fluorescence microscope equipped with a b/w cooled CCD camera 
(Hamamatsu c5985). In this work a mouse monoclonal NPMc+ antibody (T26) (1:800) or 
a mouse monoclonal NPM  (322) (Falini, 2005) was used followed by an anti-mouse Cy5 
antibody (1:100 in blocking solution, Jackson Laboratories). 
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5.5 Biochemical techniques 
5.5.1 Immunoblotting analysis 
Cells were harvested by centrifugation for 5 min at 2400 rpm and washed in cold PBS1X. 
For protein extraction cell pellet was resuspended in 8 M Urea lysis buffer (8 M Urea, 0.1 
M NaH2PO4, 0.01 M Tris pH 8.0) or RIPA buffer (10 mM Tris-HCl, pH 8.0, 1% Triton, 
0.1% SDS, 0.1% Deoxycholate, 140 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF 
and protease inhibitor cocktail Set III (EDTA-free, Calbiochem,), and incubated 1 hour on 
ice. Sonication was performed in 2-3 cycles of 10 sec each. Lysates were centrifuged at 
maximum speed for 10 min to remove debris. Lysates were quantified with a protein assay 
reagent (Bio-Rad Laboratories). 20 - 50 µg of proteins, in Laemmli loading buffer (62.5 
mM Tris-HCl pH 6.8, 2 % (w/v) SDS, 5 % (v/v) 2-mercaptoethanol and 10% (v/v) 
glycerol) and 10 µl of NOVEX ® Sharp Pre Stained protein standard (Invitrogen) were run 
onto 10% SDS-polyacrylamide gel electrophoresis and transferred by dry iBlot® Dry 
Blotting Device (Invitrogen) to nitrocellulose membranes (iBlot® Transfer Stack, 
Invitrogen) in 6 minutes. After blotting, the membranes were stained with Ponceau S 
staining solution (0.1 % Ponceau S (w/v) and 5% acetic acid (w/v) to verify equal loading 
and transfer. Membranes were briefly washed in water and blocked for 1 h at RT in 
blocking solution 5% BSA, or 5% milk, in TBS-T (20 mM Tris HCl pH 7.4, 500 mM NaCl, 
0,1 % Tween). After blocking, filters were incubated with primary antibodies, diluted in 
blocking solution, for 1-2 hours at RT or overnight at 4°C. After three washes, of 5 min 
each in TBS-T, membranes were incubated with the appropriate horseradish peroxidase 
(HRP) conjugated secondary antibody diluted in blocking solution for 30 min, at room 
temperature. Membranes were washed three times for 5 min in TBS-T and the bound 
secondary antibody was revealed using the ECL (Enhanced Chemiluminescence) plus 
method (Amersham). 
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5.6 Statistical analysis 
5.6.1 Student’s t-test 
Statistical analysis of normally distributed values (Gaussian) was performed by two-tailed 
unpaired Student’s t-test. Differences were considered significant at p-value<0.05. 
5.6.2 Survival analysis 
Survival curve was analyzed with log rank test. 
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6.1 NPMc+ initiates leukaemia in a novel mouse model 
 
6.1.1 Generation of conditional mouse model for the expression of human 
NPM1c+ mutation 
To better understand the role of the cytoplasmic mutations of the NPM1 gene in disease 
pathogenesis, a novel conditional NPM1c+ mouse model was generated in our laboratory in 
collaboration with GenOway (Leon, France). The human NPM1 mutation A cDNA has 
been inserted in the permissive hypoxanthine phosphoribosyltransferase (hpr t ) locus via 
homologous recombination in embryonic stem (ES) cells (Figure 9 A). The project was 
developed in 129Ola E14 ES cells in which 35 kb of the hpr t  gene, encompassing the 5’ 
UTR up to intron 2, is deleted. The homologous recombination between the targeting vector 
and the hpr t  locus repaired the hpr t  gene deletion and Hypoxanthine-Aminopterine-
Thymidine (HAT) medium was used to enrich for ES cell clones with correct targeting event 
(Doetschman, 1987). The targeting vector included two homologous regions to the hpr t  
locus, a STOP cassette flanked by two loxP sites that can be removed upon Cre recombinase 
induction, thus allowing for the expression of the NPM1 mutant under the control of the 
ubiquitous and strong CAG promoter (Alexopoulou et al, 2008) (Figure 9 A). ES cells that 
have undergone homologous recombination, as determined by Southern blot analysis (Figure 
9 B-C), were microinjected into C57BL/6 blastocysts to generate chimeric mice. Following 
germ-line transmission from chimeric mice, the resulting heterozygous progeny 
(NPMc+/WT) was intercrossed and analysed by Southern blot to confirm correct targeting 
of the transgene at hpr t  locus. Animals were backcrossed in C57BL/6 strain 10 times to 
obtain a pure strain. Considering the location of the hpr t  locus on the X chromosome, the 
present study was developed using hemizygous NPMc+/WT males or homozygous 
NPMc+/NPMc+ females, hereafter, these mice are collectively referred to as NPMc+ mice. 
All the animals carrying the NPMc+ transgene born at Mendelian ratio, they were viable and 
fertile, and they did not manifest any gross phenotypic abnormalities. 
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Figure 9 - Generation of a conditional mouse model with the human NPM1 mutation.  
A. Strategy for targeted insertion of the human NPM1 mutation A cDNA into the murine h p r t  locus. The 
picture depicts the structure of the mouse h p r t  genomic locus in wild type (WT) mice (on the top), in h p r t  
partially deleted E14 ES cells (upper middle), the targeting vector (lower middle) and the target allele (bottom). 
Diagram is not drawn to scale. B. Schematic representation of the h p r t  locus in E14 ES cells (on the top) and 
the homologous targeted allele (on the bottom) with the relevant restriction sites for the Southern blot analysis. 
C. Southern blot analysis confirmed homologous recombination. (Image adapted from GenOway).  
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6.1.2 Conditional expression of NPM1 mutation in the haematopoietic 
compartment 
In order to restrict the expression of the NPMc+ protein to the haematopoietic 
compartment and avoid unknown effects linked to the expression of the mutated protein in 
other tissues, bone marrow mononuclear cells (BM-MNC) from NPMc+ (8 to 10 weeks 
old) or age matched control wild type (WT) mice were purified, treated ex vivo with a 
recombinant Cre protein fused with the HIV-derived TAT protein (TAT-Cre) and then 
transplanted in C57BL/6 CD45.1 recipient irradiated mice (Figure 10). The recombinant 
TAT-Cre protein is able to penetrate into the cells and to target floxed sequences (Peitz et al, 
2002) thus allowing the expression of the NPMc+ protein. 
 
 
 
Figure 10 - Schematic representation showing experimental design to induce NPM1c+  expression in 
the haematopoietic compartment.  
BM-MNCs were isolated from WT or NPMc+ mice and treated ex vivo with TAT-Cre to induce 
recombination and deletion of the STOP cassette. TAT-Cre treated cells have been transplanted into 6.5 Gy 
irradiated C57BL6/ CD45.1 mice.  
 
The efficiency of TAT-Cre mediated recombination and successful expression of the NPM 
mutant protein was assessed both by western blot and immunofluorescence using an 
antibody that specifically recognizes only the NPM mutant protein (T26) (Gruszka et al, 
2010). Western blot analysis clearly revealed the expression of the NPMc+ protein upon 
TAT-Cre treatment (Figure 11A) and the percentage of recombined cells was evaluated by 
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immunofluorescence (38.9% +/- 5.15 in all experiments). As previously reported (Falini et 
al, 2005), the mutated protein clearly accumulated in the cytoplasm (Figure 11B). The 
delocalization of the mutated protein was further confirmed using an antibody that 
recognizes both NPM WT and mutated (322) (Falini et al, 2005). In this case, NPM 
displayed nucleolar/nuclear staining in control cells and both nuclear/cytoplasmic staining 
in NPMc+ expressing cells (Figure 11C). 
 
 
 
Figure 11 - Expression of the NPM1 mutation in TAT-Cre treated NPMc+ BM-MNCs.  
A. Western Blot analysis of NPMc+ protein expression with mAb specific to NPM1mut A protein (T26) in 
TAT-Cre treated NPMc+ BM-MNCs. OCI-AML3, a NPMc+ expressing cell line, was used as positive 
control; NT, not treated NPMc+ BM-MNCs. B. Immunofluorescence analysis of TAT-Cre treated NPMc+ 
BM-MNCs labelled with the same mAb used in (A) (red staining). NPMc+ cytoplasmic staining is highlighted 
merging the red staining with DAPI nuclei staining (merge). C. Immunofluorescence analysis of TAT-Cre 
treated NPMc+ or WT BM-MNCs labelled with an antibody that recognizes both the WT and the mutant 
NPM (red staining) (clone 322). Original magnification 60X. Scale bar = 10 µm. 	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In order to evaluate the extent of engraftment, 4 weeks after bone marrow transplantation 
(BMT) mice were tested for donor haematopoietic reconstitution using the CD45.1 and 
CD45.2 allelic variant discrimination system (Figure 12A). As shown in figure 12B, the 
average reconstitution in mice was 84,45%±3,8 for NPMc+ animals and 85,02%±4,67 for 
WT animals, remarkably, the reconstitution was maintained during 24 months of follow up 
(Figure 12C). Moreover, NPMc+ protein expression was detected in the peripheral blood of 
transplanted mice 4 months after bone marrow transplantation (Figure 12D), indicating 
effective long-term reconstitution supported by NPMc+ expressing haematopoietic stem 
cells (HSC). 
Altogether these data indicate that we have generated a novel mouse model expressing the 
cytoplasmic delocalized NPMc+ mutation whose expression is restricted to the 
haematopoietic compartment. This model represents a useful tool to study the impact of 
NPMc+ mutation on both haematopoiesis and leukaemogenesis. 
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Figure 12 - Haematopoietic reconstitution of NPMc+ and control BMT mice.  
A. Representative FACS plot for gating strategy. Peripheral blood was analysed for the relative contribution of 
donor (CD45.2) and recipient (CD45.1) mice. B. Summary chart representing CD45.2 and CD45.1 chimerism 
in peripheral blood (PB) of WT or NPMc+ BMT mice at 4 weeks after BMT. C. Summary representing the 
CD45.1 and CD45.2 chimerism in peripheral blood of   WT or NPMc+ BMT mice 4 weeks after BMT and at 
time of death. (WT N=17; NPMc+N=15) D. Western blood of BMT mice 4 months post-BMT. (PB_1,2,3 
represent blood from three NPMc+ BMT mice; PB_wt represents blood from a control WT BMT mouse; 
OCI_AML3 is used as positive control for NPMc+ expression.A. Western Blot analysis of NPMc+ protein 
expression with mAb specific to NPM1mut A protein (T26) in TAT-Cre treated NPMc+ BM-MNCs. OCI-
AML3, a NPMc+ expressing cell line, was used as positive	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6.1.3 NPM1c+ mice develop leukaemia late in life  
To study the ability of NPMc+ mutation to promote leukaemia development in our model, 
NPMc+ and WT BMT mice were allowed to age. Mice were monitored three times at week 
for general health conditions by global examination and palpation. Every month peripheral 
blood was collected and detailed haematological analysis was performed by differential 
blood cells count and blood smear inspection. Animals were sacrificed at first signs of pain 
and organs and cells were collected for detailed studies, as described below. Overall survival 
of the two groups of animals was not significantly different with a median survival of 581 
and 694 days in NPMc+ and control mice, respectively (Figure 13A). Strikingly, 33.3% of 
NPMc+ animals developed leukaemia late in life compared to no leukaemia derived death in 
control mice (p=0.04) (Figure 13B), while the incidence of diseases other than leukaemia did 
not differ between the two groups (Figure 13C and Table 1). Interestingly, two NPMc+ 
animals died of severe anaemia with myelodysplastic features in the bone marrow and 
peripheral blood smear. 
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Figure 13 - The NPMc+ mutation promotes leukaemia development in NPMc+ BMT mice.  
A. Kaplan-Mayer survival curve of NPMc+ and WT BMT mice showing a comparable overall survival 
between the two groups. B. Kaplan-Mayer curve showing statistically significant mortality due to AML in 
NPMc+ cohort compared to WT mice. C. Pie chart representation of disease incidence in NPMc+ or WT 
mice. AML=Acute myeloid leukaemia; MDS, myelodysplastic syndrome; B, T= B or T lymphoma. N=17 WT 
and N=15 NPMc+ BMT animals.  
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                              RESULTS 
51	  
Table 1. Diagnostic findings for NPMc+ and WT transplanted mice. 
 
Mouse ID Genotype Putative cause of death 
N_1 NPMc+ AML 
N_2 NPMc+ AML 
N_3 NPMc+ AML 
N_4 NPMc+ AML 
N_5 NPMc+ AML 
N_6 NPMc+ Severe anaemia (MDS) 
N_7 NPMc+ Severe anaemia (MDS) 
N_8 NPMc+ B-lymphoma 
N_9 NPMc+ B-lymphoma 
N_10 NPMc+ T-lymphoma 
N_11 NPMc+ T-lymphoma 
N_12 NPMc+ Stomach cancer 
N_13 NPMc+ Retrobulbar tumour 
N_14 NPMc+ Retrobulbar tumour 
N_15 NPMc+ Not exanimated 
W_1 WT Sacrificed 
W_2 WT Sacrificed 
W_3 WT Sacrificed 
W_4 WT Sacrificed 
W_5 WT Sacrificed 
W_6 WT B-lymphoma 
W_7 WT B-lymphoma 
W_8 WT B-lymphoma 
W_9 WT T-lymphoma 
W_10 WT T-lymphoma 
W_11 WT T-lymphoma 
W_12 WT Unknown (dermatitis) 
W_13 WT Retrobulbar tumour 
W_14 WT Retrobulbar tumour 
W_15 WT Cancer stomach 
W_16 WT Ovarian cancer 
W_17 WT Ovarian cancer 
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NPMc+ mice developed AML between 536 and 637 days with a median survival of 564 
days (Figure 13B). Detailed histological analyses revealed that bone marrow samples of 
NPMc+AML mice showed an overall increase in cellularity, with a myeloid hyperplasia and 
signs of dysplasia of the erythroid and megakaryocyte series. The myeloid compartment was 
left-shifted, with an increase in immature cells and overall myeloblasts prevalence (Figure 
14). Neoplastic aggregates and nodules composed by large cells with abundant cytoplasm 
and indented nuclei, morphologically suggesting a monocyte differentiation, were observed 
in extramedullary sites, including spleen, liver, kidneys and lungs (Figure 14). Blood smears 
were characterized by the presence of a high number of blasts (Figure 14). These animals 
displayed leucocytosis, thrombocytopenia, anaemia and splenomegaly (Figure 15) and the 
expression of the mutated NPM protein was clearly detectable in the infiltrated bone 
marrow derived cells (Figure 16). 
 
 
 
Figure 14 - Leukaemia development in NPMc+ BMT mice  
Representative images of haematoxylin and eosin (H&E)-stained bone marrow (BM), spleen and liver section 
from NPMc+ leukaemic mice or control WT mice. May-Grunwald Giemsa staining of blood smears is shown 
in the right panel.  
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Figure 15 - Significant clinical alteration in leukemic NPMc+BMT mice.  
A total of 50 uL of peripheral blood was collected from moribund mice along with samples from control mice 
and evaluated through an automated peripheral blood analyzer. The analysis showed leukocytosis (A), 
thrombocytopenia (B) and anaemia (C). Necropsy indicated splenomegaly (D). (NPMc+ N=5; WT N=5).  
 
 
 
Figure 16 - NPMc+ protein is expressed in leukaemic blasts isolated from NPMc+ mice. 
Western Blot analysis of NPMc+ protein expression with a mAb specific to NPM1mutA protein (T26) in 
blasts isolated from NPMc+ AML leukaemic mice. A NPMc+ positive OCI-AML3 cell line was used as 
positive control; BM cells isolated from TAT-Cre treated WT mice as used as negative control. 
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Moreover, leukaemic cells isolated from the spleen and transplanted into sub-lethally 
irradiated syngenic mice, led to the development of a fully penetrant secondary leukaemia 
sharing the same features with the primary lesion (Figure 17). 
Altogether these data show that NPMc+ mutation is an initiating event leading to leukaemia 
development; however, the long latency and low penetrance of the disease, suggest that 
NPMc+ needs additional mutations to support a full-blown leukaemia.  
 
 
Figure 17 - NPMc+ leukaemia give rise to secondary leukaemia upon transplantation. 
 
5 independent NPMc+ leukaemia were retranslated respectively into 3 recipient irradiated mice (N=15). The 
Kaplan-Mayer survival curve of the total pool of recipient mice is reported. 
 
 
 
 
 
 
 
 
 
                                                                                                                              RESULTS 
55	  
6.1.4 Immunophenotypic characterization of the murine NPMc+ leukaemia 
To further characterize the murine NPMc+ leukaemia, FACS analysis of bone marrow 
samples were performed. The analysis showed that NPMc+ animals developed myeloid 
leukaemia with maturation (Mac1+/Gr1+) (Figure 18A-B) and in one case we observed a 
bi-phenotypic leukaemia with both myeloid (Mac1+/Gr1+) and lymphoid (B220+) lineage 
markers (Figure 18 A, Leukaemia 2). 
 
Figure 18 - NPMc+ leukaemia immunophenotyping. 
A Table showing immunophenotypic characteristic determined by FACS analysis of 5 NPMc+ leukaemia. B 
Representative plot showing flow cytometry determination of single cell suspension isolated from BM of a 
representative NPMc+ leukaemic mouse (AML3). An age matched WT mouse was used as control. 	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6.2 NPMc+ and FLT3-ITD mutations cooperate in inducing 
leukaemia development 	  
The above results show that NPMc+ oncogene can initiates leukaemia, however, the long 
latency and low penetrance strongly suggest the requirement of cooperating mutations 
selection. The most frequent co-mutated gene in NPMc+ AML patients is FLT3. In 
particular, internal tandem duplications in this gene (ITD mutations) are found in 40% of 
NPMc+ AML (Falini et al, 2005), suggesting molecular synergisms. Furthermore, the 
mutational status of FLT3 gene has important prognostic factor for NPMc+AML patients, 
as mutations in FLT3 gene count for poor prognosis (Whitman et al, 2001)(Schnittger et al, 
2002). In order to test the putative cooperation between the two genetic lesions in leukaemia 
development, we crossed the conditional NPMc+ mice with a constitutive heterozygote 
FLT3-ITD knock-in animal model (Lee et al, 2007) to generate double transgenic mice. The 
FLT3-ITD murine model, used in this study, has been described to develop a 
myeloproliferative disease that does not progress to acute myeloid leukaemia (Lee et al, 
2007). BM-MNCs were isolated from double transgenic mice, treated ex vivo with TAT-Cre 
to induce expression of NPMc+ protein and transplanted into lethally irradiated CD45.1 
syngeneic mice. Hereafter the BMT mice were referred to as NPMc+/FLT3-ITD mice. 
Strikingly, NPMc+/FLT3-ITD double mutant mice developed leukaemia very rapidly and 
with full penetrance. All NPMc+/FTL3-ITD mice died between 35 and 147 days post 
transplantation, with a median survival of 72 days (Figure 19). As previously observed in the 
NPMc+ leukaemic mice, splenomegaly, leucocytosis, anaemia and thrombocytopenia were 
found in the NPMc+/FLT3-ITD leukaemic animals (Figure 20).	  	   
                                                                                                                              RESULTS 
57	  
	  
Figure 19 - NPMc+ and FLT3-ITD mutations efficiently cooperate to develop leukaemia. 
Kaplan-Mayer survival curve of NPMc+/FLT3-ITD mice showing a potent synergism in leukaemia 
development. WT (N=16), FLT3-ITD (N=16) or NPMc+/FLT3-ITD (N=16) mice and treated with TAT-
Cre.	  
                                                            
 
Figure 20 - Significant clinical alteration in leukemic NPMc+/FLT3-ITD BMT mice. 
A total of 50 uL of peripheral blood was collected from moribund mice along with samples from control mice 
and evaluated through an automated peripheral blood analyzer. The analysis showed leukocytosis A, 
thrombocytopenia B and anaemia C. Necropsy indicated splenomegaly (D). (FLT3-ITD N=16; 
NPMc+/FLT3-ITD N=16). 
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Bone marrow histological inspection of NPMc+/FLT3-ITD mice, revealed a complete 
replacement of the hematopoietic series by a monotonous proliferation of blasts. In most of 
the cases, large neoplastic nodules composed of cells with the same features of those 
observed in the bone marrow were detected in extramedullary sites including spleen, liver, 
kidneys, lungs, gut and heart (Figure 21 for representative data). Blood smears were 
characterized by the occurrence of a high number of blasts.  
	  	  
Figure 21 - Leukaemia development in NPMc+/FLT3-ITD BMT mice.   
A total of 50 uL of peripheral blood was collected Representative images of haematoxylin and eosin (H&E)-
stained bone marrow (BM), spleen and liver section from NPMc+/FLT3-ITD leukaemic mice or control WT 
mice. May-Grunwald Giemsa staining of blood smears is shown in the right panel. 	  
 
Flow cytometry analysis of bone marrow from NPMc+/FLT3-ITD leukaemic animals 
showed that 62.5% of mice (10 out of 16) developed myeloid leukaemia with maturation 
(Mac1+/Gr1+), whereas 37.5% (6 out of 16) developed a biphenotypic leukaemia: 5 cases 
with both myeloid (Mac1+/Gr1+) and B-lymphoid (B220+) lineage markers and 1 case 
with both myeloid (Mac1+/Gr1+) and T-lymphoid (CD3+) lineage markers (Table 2). 
The expression of the mutated NPM protein in the BM of leukaemic mice was confirmed 
by western blot analysis (Figure 22).  
The short latency and the full penetrance of leukaemia emergence clearly demonstrate the 
striking cooperation between NPMc+ and FLT3-ITD mutations. 
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Table 2. Table showing immunophenotypic characteristic determined by FACS 
analysis of 16 NPMc+/FLT3-ITD leukaemia. 
 
Bone marrow GR1+/Mac1- GR1+/Mac1+ GR1-/Mac1+ B220 CD3 
Leukaemia_1 10.88 72.2 9.37 1.53 1.7 
Leukaemia_2 23.8 55.5 8.8 8.09 10.7 
Leukaemia_3 3.1 89.6 1.1 2.1 0.8 
Leukaemia_4 5.6 83.6 4.3 0.5 5.2 
Leukaemia_5 10.9 70.1 2.9 5.3 12.4 
Leukaemia_6 8.3 58.9 8.9 49.9 0.1 
Leukaemia_7 16.8 70.4 5.9 16.2 9 
Leukaemia_8 11.1 45.4 23 58 3.3 
Leukaemia_9 18.8 67 2.7 32.9 3.89 
Leukaemia_10 2.6 74.5 12.6 3.8 4.6 
Leukaemia_11 1.4 32.1 0.5 54.2 12.1 
Leukaemia_12 3 13.2 0.1 2.5 51.7 
Leukaemia_13 7.65 89.9 1.09 12.4 3.24 
Leukaemia_14 9 24 2 27.3 0.15 
Leukaemia_15 21.9 58.2 4.56 16.3 0 
Leukaemia_16 21.7 42.5 13.3 39.3 12.3 	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 22 - NPMc+ protein is expressed in leukaemic blasts isolated from NPMc+/FLT3_ITD mice.  
Western Blot analysis of NPMc+ protein expression with a mAb specific to NPM1mutA protein (T26) in 
blasts isolated from 5 representative NPMc+/FLT3_ITD AML leukaemic mice (1-5 N/F leukaemia) . A 
NPMc+ positive OCI-AML3 cell line was used as positive control; BM cells isolated from TAT-Cre treated 
WT mice as used as negative control. 
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6.3 NPMc+ Lin- cells and NPMc+ leukaemic blast showed a Hox 
gene signature 
The expression profile of patients with NPMc+AML has been previously correlated with 
the overexpression of homeobox-containing transcription factor genes (Alcalay et al, 2005). 
Therefore, to further validate our model, the expression of few Hox gene was evaluated 
both in lineage markers negative (lin-) cells isolated from pre-leukemic mice (3 months old) 
and in BM blasts derived from NPMc+ and NPMc+/FLT3-ITD leukaemic animals. 
Quantitative RT-PCR analysis confirmed that the same Hox gene found overexpressed in 
human NPMc+ AMLs were up regulated both in NPMc+ lin- pre-leukemic cells and in 
NPMc+ or NPMc+/FLT3-ITD leukaemic blasts (Figure 23). 
This data confirms the capability of our mouse model to recapitulate unique features of 
NPMc+ AML. Moreover, the up-regulation of the Hox genes in the preleukemic phase 
indicates that the deregulation of the Hox gene is an early mark of NPMc+ expression in the 
more undifferentiated haematopoietic compartment and it may contribute to the leukemic 
process. 
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Figure 23 - HOX gene upregulation in NPMc+ lin-cells and NPMc+, NPMc+/FLT3-ITD leukemic 
blasts. Expression of Hox genes analysed by Q-PCR using mRNA from lin- cells isolated from TAT-Cre 
treated WT or NPMc+ BMT mice and from 5 NPMc+ AMLs and 5 NPMc+/FLT3-ITD (NF) AMLs . 
Expression was standardized with Tata Box Protein (TBP) and normalized against the control WT RNAs. 
*p<0.05  
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6.4 Biological impact of the NPMc+ expression in the 
haematopoietic stem and progenitor cell compartment 	  	  
An open challenge to leukaemia field and, more in general, to cancer cell biology is the 
acquisition of a profound knowledge of the molecular pathways that induce the transition 
from normal to malignant cells and finally lead to the establishment of malignant clonal 
dominance. HSCs are thought to be the main target of early transforming events because 
they are long-lived cells with self-renewal ability and thus they can potentially fix and 
propagate initial mutations. The population of HSCs that harbour the early mutations, but 
not the entire set of alterations necessary to become frank leukaemia, could be referred to as 
pre-leukemic stem cells (pre-LSC). Pre-leukemic SCs, by definition, maintain the capability 
to differentiate into the full range of mature myeloid and lymphoid cells. 
At present, the impact of cytoplasmic mutations of the NPM1 gene on haematopoietic stem 
and progenitor cells compartment is completely obscure. In the present study, the NPMc+ 
mouse was used as a model system to investigate how the mutated NPM protein affects 
normal haematopoiesis and to study the underlying deregulated mechanisms that may be 
responsible for HSC transformation into LSCs. 
 
 
6.4.1 Generation of NPMc+/YFP mice 
TAT-Cre treatment of BM-MNCs leads to approximately 50% recombination efficiency in 
our experimental conditions (as reported in paragraph 6.1.2). Therefore, in order to track in 
vivo NPMc+ expressing cells, conditional NPMc+ mice were crossed with conditional 
ROSA26eYFPreporter mice (Srinivas, 2001), which express the Yellow Florescent Protein 
(YFP) upon Cre mediated recombination. To test whether YFP signal directly correlates 
with NPM mutant protein expression, BM-MNCs isolated from double transgenic 
NPMc+/YFP mice, were subjected to TAT-Cre treatment and then FACS sorted into two 
distinct subpopulations: the YFP positive (YFP+) and the YFP negative (YFP-) cell sub-
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fractions (Figure 24 A-B). Western blot analysis revealed that only YFP+ sorted cells 
expressed the mutant protein (Figure 24 C). This data indicates that TAT-Cre mediated 
recombination occurs both at the y fp  and npm mutant transgenic loci with equal efficiency 
within the same cell. Therefore, YFP signal can be used as mirror for NPMc+ expressing 
cells in the NPMc+/YFP model system. 	  
 
  
Figure 24 - YFP signal marks NPMc+ protein expression.  
(A) Schematic representation of the experimental approach. BM-MNCs isolated from NPMc+/YFP mice were 
TAT-Cre treated (1). Recombined cells are depicted as yellow circles, whereas not recombined cells as white 
circles. The heterogeneous populations were FACS sorted according to YFP expression into YFP+ and YFP- 
subpopulations (2). The efficiency of the TAT-Cre mediated recombination at the hprt and rosa26 loci was 
tested in in C. (B) Representative FACS plot showing gating strategy. (C) Western blot assay showing NPMc+ 
expression in the pre-sort sample, in the YFP- (Y-) and YFP+ (Y+) sorted fractions isolated from 
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NPMc+/YFP mice (NY). YFP- (Y-) and YFP+ (Y+) sorted fractions isolated from YFP mice (Y) were used 
as negative control for NPMc+ expression. NPMc+ positive OCI-AML3 cell line was used as positive control. 
 
 
6.4.2 NPMc+ allele expression increases the haematopoietic reconstitution 
ability 
HSCs supply all blood cells throughout life by making use of their self-renewal and 
mutilineage differentiation capabilities (Osawa et al, 1996). Therefore, they are crucial for 
long term reconstitution of haematopoiesis on transplantation into recipients with bone 
marrow ablation (Verfaillie, 2002). Short term haematopoietic reconstitution is exhausted 
prior to 4 months post BMT, therefore this time point is used to test long term regenerative 
potential (Morrison & Weissman, 1994). 
To evaluate the impact of NPMc+ expression on HSC function during hematopoietic 
reconstitution, competitive BMT experiments were performed (Szilvassy et al, 1990).  BM-
MNCs were isolated from NPMc+/YFP mice or control YFP mice, TAT-Cre treated and 
YFP+ FACS sorted. Then, CD45.2 YFP+_WT or YFP+_NPMc+ expressing BM-MNCs 
were mixed in a 1:1 ratio with wild type CD45.1 competitor BM-MNCs and injected into 
lethally irradiated recipient mice. Mice were bled every 4 weeks and analysed for occurrence 
of CD45.2 chimerism in the peripheral blood. As shown in Figure 25, in mice transplanted 
with the NPMc+ expressing BM cells (red bars) we observed an increased percentage of 
YFP+ cells compared to the WT counterpart (white bars) suggesting an increased ability to 
outcompete the wild type CD45.1 BM cells and an increased capacity to contribute to the 
haematopoietic reconstitution.  
 
 
 
                                                                                                                              RESULTS 
65	  
 
Figure 25 - Haematopoietic reconstitution potential of NPMc+ expressing BM-MNCs. 
Percentage of CD45.2 in the peripheral blood of recipient mice (N=4) at different time points. The image 
referred to one of two independent experiments. * P value<0.05. 
 
 
6.4.3 NPMc+ allele expression expands the pool of LKS and Long Term (LT)-
HSC 
The observed increased repopulating ability of NPMc+ HSC expressing cells, prompted us 
to investigate more in detail the haematopoietic stem/progenitor cell compartment (HSPC) 
in transplanted mice by immunophenotyping analysis. To address this point, mice 4 months 
post BMT were FACS analysed according to the HSPC unique cell surface profile (see 
materials and methods) (Spangrude et al, 1988) (Okada et al, 1992), (Figure. 26 A for 
representative results). The NPMc+ expressing BM population showed a significant increase 
in the total number of lineage negative, c-Kit+, Sca+ cells (LKS), which define the 
compartment containing both the long term (LT) and short term (ST) repopulating HSC 
and the multipotent progenitors (MPP). As we further dissected the LKS compartment 
based on the FLK and CD34 surface markers, we realised that both the LT and ST HSC are 
significantly expanded while no difference was appreciated in the MPP compartment (Figure 
26 B). Interestingly, analysing the relative quantity of LT-HSC, ST-HSC and MPP in the 
LKS compartment, we observed a significant increase of the LT-HSC frequency and a 
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corresponding decrease in the MPP population (Figure. 26 C). These data collectively 
suggest that NPMc+ expression expands the most undifferentiated haematopoietic 
compartment and that this expansion is mainly due to its effect on the LT-HSC population. 
 
 
 
Figure 26 - HSC expansion in NPMc+ mice.  
(A) Representative flow cytometric-gating strategy. Numbers (B) and frequency (C) of HSPC subpopulations 
in NPMc+ and WT BM. Images are the mean of 7 animals evaluated in 3 independent experiments. *p value 
<0.05  
 
 
To confirm that the observed increased stem cells number was not due to an in vitro 
expansion of the HSC/progenitor population prior to the transplantation, NPMc+/YFP 
mice were crossed with a tamoxifen inducible Cre-ERTM mouse strain (Hayashi & 
McMahon, 2002) to allow for inducible in vivo Cre recombination. Triple transgenic mice 
along with control Cre-ER/YFP mice were treated in vivo with tamoxifen in order to 
induce the translocation of Cre into the nucleus followed by Cre-dependent recombination. 
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Ten days after tamoxifen injection, BM-MNCs were purified and analysed as described in 
Figure 26 A to evaluate the frequency of HSPC and then transplanted in lethally irradiated 
syngeneic CD45.1 recipient mice. These mice were sacrificed 4 month after BMT and 
evaluated for their HSPC composition. This experiment allowed us to evaluate the 
frequency of NPMc+ expressing and WT HSPC prior and 4 months after BMT. As shown 
in Figure 27, after 4 months we could appreciate a significant expansion of the LKS and LT-
HSC population only in the NPMc+ expressing HSPC. 
 
 
 
Figure 27 - HSC expansion in NPMc+ mice.  
Summary graphs representing the frequency of LKS, LT-HSCs, ST-HSCs and MPP subpopulations in Cre-
ER/YFP (WT) and NPMc+/ Cre-ER/YFP (NPMc+) mice at transplantation (dark red bars) and 4 month 
after BMT (light red bars). At transplantation N=1; 4 months post BMT N=5. *p value <0.05 	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6.4.4 NPMc+ expression leads to increased proliferation within normally 
quiescent LT-HSC compartment. 
In the effort to determine the mechanisms of NPMc+ driven LKS and LT-HSC expansion, 
a possible hypothesis is that this oncogenic mutation increases cell proliferation. To evaluate 
the proliferation rate of WT and NPMc+ expressing BM cells we performed an in vivo 
BrdU incorporation assays (Passegue et al, 2005). Bone marrow was harvested 12 h post 
BrdU injection and stained both with anti BrdU and HSCP cell surface markers antibodies. 
The percentage of BrdU positive cells in each hematopoietic compartment was evaluated by 
FACS analysis. As shown in Figure 28, the NPMc+ expressing LKS compartment and its 
sub-populations (LT/ST-HSC and MPP) are characterized by an increased BrdU 
incorporation rate. These data support a putative role of NPMc+ in promoting cell cycle 
progression in the most undifferentiated hematopoietic compartment. 
 
 
 
Figure 28 - NPMc+ HSPCs show increased proliferation.   
BM-MNCs were harvested from WT_YFP+ and NPMc+_YFP+ transplanted mice 12 hr after BrdU 
injections and FASC analyzed according to the HSCP cell surface markers and the BrdU staining. . Percentage 
of BrdU positive cells in the LKS, LT-HSC, ST-HSCs and MPP compartments is reported. N=3.  
*p value <0.05. 
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6.4.5 Higher proliferative rate in LT-HSC is not associated to loss of quiescent 
LT-HSC pool 
Recent studies have shown that a small number of highly quiescent HSC have the greatest 
self-renewal potential and are responsible for haematopoietic reconstitution after injury, as 
upon treatment with the myelosuppressive agent 5-fluorouracil (5-FU) (Wilson et al, 2008). 
The increased proliferation rate of NPMc+ expressing HSCs raised the possibility that the 
quiescent pool of HSC might be recruited into cell cycle upon oncogene expression and 
eventually exhausted. To address this question, NPMc+ and control mice were 
intraperitoneally injected with 5-FU every 7 days to continuously deplete regenerating 
progenitor population. 5-FU kills cycling hematopoietic cells and challenges the quiescent 
pool of HSC to entry the cell cycle and to repopulate the depleted bone marrow (Harrison 
& Lerner, 1991) The survival curves of 5-FU treated animals showed increased resistance in 
NPMc+ expressing mice (Figure 29). This result suggests that, despite the increased 
proliferative rate in the presence of NPMc+, the reservoir of quiescence HSC is expanded 
and their self-renewal ability is maintained.  
  
Figure 29 - NPMc+ mice show high survival to 5-Fu injection.   
Kaplan-Mayer survival curve of control and NPMc+ mice injected intraperitoneally with 5-FU every 7 day. 
 P value<0.05 
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6.4.6 NPMc+ does not expand replicative potential in vitro 
 
We have shown that NPMc+ expressing HSC have an increased proliferation rate, and as a 
consequence, the HSC pool is expanded yet maintaining the self-renewal and repopulating 
ability. Since the putative leukaemia initiating stem cell should be characterized by limitless 
self-renewal activity (Lane & Gilliland, 2010) we wanted to test if NPMc+ expression 
correlates with extended self-renewal ability. We have set up a serial transplantation 
experiment starting from the experimental scheme shown in Figure 24 A. CD45.2 NPMc+-
YFP+ or WT_YFP+ sorted cells were transplanted in lethally irradiated CD45.1 mice, 4 
weeks after BMT the peripheral blood was analysed and the extent of engraftment 
established evaluating the percentage of CD45.2 positive cells (not shown). Three months 
after BMT mice were sacrificed, CD45.2 bone marrow cells purified and re-transplanted in a 
second CD45.1 lethally irradiated recipient. In normal circumstances, such a protocol should 
be repeated until the death of the transplanted mice because of the progressive exhaustion 
of the HSC pool within the serial transplanted BM cells. Therefore, in this assay, the number 
of successful serial transplantation is an indirect measure of the self-renewal potential of the 
initial HSC pool. Unfortunately, in our hands after the third serial transplantation, mice 
transplanted with the NPMc+ expressing BM cells, developed leukaemia and died, 
preventing the completion of the assay (Figure 30). 
As surrogate experiment we performed an in vitro serial replating assay in methylcellulose in 
the presence of IL3, IL6 and stem cell factor (SCF) cytokines. Equal number of YFP+ WT 
and NPMc+ expressing BM cells were purified from transplanted mice, plated and cultured 
for 7-10 days, then colonies were counted and cells were collected and replated. As shown in 
Figure 31 in the first plating we scored an increased number of colonies in NPMc+ 
expressing cells confirming the expansion of the more undifferentiated LKS compartment. 
By the second plating the difference in colony number between NPMc+ and WT cells was 
greatly reduced and both samples exhausted their in vitro replicative potential by the 7th 
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passage. Within the limitation of the assay, these data suggest that NPMc+ does not extend 
the replicative potential of HSCP cells in vitro. 
 
 
Figure 30 - Serial BMT accelerates leukaemia onset in NPMc+ mice.  
Kaplan-Mayer survival curve of mice serially transplanted with NPMc+ BM-MNCs. BM-MNCs were 
harvested every 3 months, YFP+ sorted and then retransplanted in lethally irradiated CD45.1 mice. At third 
passage mice developed leukaemia.   
 
 
 
Figure 31 - NPMc+ increases the number of colony forming unit (CFU) but not expands replicative 
potential in vitro.  
BM-MNCs from YFP+_NPMc+ and YFP+_WT transplanted mice were purified and serially plated on 
M3434 methylcellulose ((Lee et al, 2007). The number of colonies at each plating is reported. 
                                                                                                                      DISCUSSION 
72	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7. Discussion 	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Acute Myeloid Leukaemia (AML) is a heterogeneous disease characterized by uncontrolled 
proliferation of myeloid blast cells and interference of the normal hematopoietic process. It 
represents the most frequent type of leukaemia in adults, with an estimated worldwide 
annual incidence of 3-4 cases per 100,000 people and a mortality of 4-6 cases per 100,000 
people every year (Fey, 2009). The prognosis for patients with AML varies dramatically and 
is strongly influenced by a number of factors, including age, performance status, and, in 
particular, the karyotype at the time of diagnosis provides the most important independent 
prognostic information in adults with AML (Byrd et al, 2002). However, 40-50% of 
patients do not have clonal chromosomal aberrations (Mrozek et al, 2004). This group of 
cytogenetically normal AML is currently categorized as intermediate-risk group, although it 
needs more profound assessment (Tsimberidou & Estey, 2006) (Lowenberg et al, 2003). In 
recent years, the advent of progress in technology, as the high throughput sequencing 
methods, has provided the means for alternative approaches to the identification of disease 
alleles in NK-AML (Dohner, 2007) (Bullinger et al, 2004). Many of these patients carry 
recurrent genetic alterations that lead to changes in gene expression, such as mutations or 
polymorphisms (Schlenk et al, 2008). Somatic mutations in AML involve partial tandem 
duplications (PTD) of the MLL gene (Caligiuri et al, 1994), internal tandem duplication 
(ITD) (Nakao et al, 1996) or mutations in the tyrosine kinase domain (TKD) (Yamamoto 
et al, 2001) of the FLT3 gene, mutations in the NPM1 gene (Falini, 2005), CEBPA gene 
(Pabst et al, 2001), NRAS gene (Bos et al, 1985), DNMT3A (Yamashita, 2011) and 
IDH1(Mardis, 2009). In particular, the cytoplasmic mutations of the NPM1 gene have been 
found to be the most frequent genetic alteration associated to adult NK-AML (60% of 
NK-AML and 35% of all AML) (Falini et al, 2005). Importantly, many of those mutations 
represent significant prognostic factors, allowing a more differential prognosis to help 
guide treatment choices (Schlenk et al, 2008). For instance, FLT3-ITD have been 
associated with short relapse-free and overall survival (Whitman et al, 2001)(Schnittger et 
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al, 2002), whereas a more favourable outcome is associated with cytogenetically normal 
cases of AML with mutations in NPM without concomitant FLT3 alterations (Thiede et al, 
2006). However, to formally demonstrate whether those mutations represent real driven 
events for tumour initiation or progression it is critical the development of accurate mouse 
models able to recapitulate the main feature of the human disease. Animal models provide 
incomparable insights into the mechanisms of leukaemia development and permit 
exploration of the molecular pathways of disease initiation, progression and maintenance in 
a more unbiased way then cell line (Ablain et al, 2013). Therefore, mouse models allow for 
the identification of potential new therapeutic targets and importantly they could be used 
as clinical purposes platform to test the efficiency of new therapeutic drugs. 
The present PhD project has been developed in an effort to clarify the significance of the 
cytoplasmic mutant of the NPM1 gene in leukaemia onset through the characterization of a 
novel conditional mouse model and the identification of the alterations induced by the 
oncogene during the pre-leukaemic phase preceding the evolution to the frank malignancy. 
We reason that those mechanisms are the key elements in NPMc+ driven transformation.  
In our experimental setting, restricted hematopoietic expression of the most common 
NPM1 genetic lesion leads to leukaemia onset in mice. This result definitively clarifies the 
relevance of NPMc+ oncogene expression to leukaemia onset and demonstrates that the 
mutated protein is an initiating lesion that prone to the establishment of the malignant 
clone.  
The murine NPMc+ leukaemia share many features with the human NPMc+AML. First, 
based on morphological and immunophenotypic evaluation, the majority of the murine 
NPMc+ leukaemia could be classified as myelomonocitic/monocytic leukaemia, similar to 
the human M4-M5 AML subgroups according to the FAB classification. This characteristic 
is consistent with the fact that these subgroups are the most representative sub-types of the 
human NPMc+AMLs (Falini et al, 2005). In addition, a striking feature the human 
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NPMc+AML is the association to a unique gene expression profile characterized by up-
regulation of numerous members of the homeodomain-containing family of transcription 
factors, including HOX and TALE genes (Alcalay et al, 2005). These genes are involved in 
the maintenance of a stem cell phenotype, since their expression is higher in HSCs and 
decreases during normal differentiation (Alharbi et al, 2013), (Magli et al, 1991). In 
accordance with these data, we found that NPMc+ murine blasts shown increased 
expression of these genes. Moreover, we observed that undifferentiated bone marrow cells 
(lineage marker negative cells, Lin-) isolated from NPMc+ expressing mice in the pre-
leukaemic phases (3 months old mice) displayed a similar gene deregulation. The 
identification of this signature during the pre-leukemic phase suggests that the deregulation 
of a stem cell phenotype is one of the underlying abnormal mechanisms imposed by 
NPMc+ oncogene. The exact mechanism of the association between the NPM1 mutation 
and the up-regulation of HOX genes is still unclear. A possible explanation is that NPMc+ 
directly disturbs the expression of HOX genes, or alternatively, that NPM1 mutation arrest 
the differentiation of early hematopoietic progenitors in which HOX gene expression is 
up-regulated (Rau & Brown, 2009).  Indeed, numerous studies have shown that 
deregulation of HOX genes is associated to haematopoietic malignancies. In this regards, 
first evidences came from the fact that their overexpression in mouse bone marrow leads 
to myeloproliferative disease and/or leukaemia. For instance, Hoxa9 overexpression 
enhances HSC expansion and myeloid progenitor proliferation and, with a long latency, 
leads to leukaemia (Kroon et al, 1998; Thorsteinsdottir et al, 1999). In human leukaemia, 
HOX genes overexpression could be caused by chromosomal rearrangements that involve 
their upstream regulator such as MLL. Normally, MLL positively regulates the transcription 
of HOX genes by maintaining their expression through direct binding to a proximal 
promoter (Milne et al, 2002). MLL fusion proteins activate HOX gene transcription more 
efficiently then alone (Slany, 2009). As a consequence, myeloid differentiation is blocked 
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and proliferation is enhanced. Moreover, HOX genes can promote the development of 
AML by forming chimeric fusions with other genes, such as the NUP98 (Borrow et al, 
1996; Nakamura, 2006).  
Leukaemia onset represents the only significant variance between the survival curve of 
NPMc+ cohort and control animals, however, we also reported emergence of MDS cases 
in NPMc+ mice. Those animals died of severe anaemia showing hypocellularity in bone 
marrow with dysplastic features in the erythroid and megakaryocytic series (data not 
shown). Our observation raises the possibility of a more complex correlation between 
NPMc+ mutations and hematological disease pathogenesis. Indeed, while the occurrence 
of NPMc+ mutation in de novo AML is very well documented (Falini et al, 2005), its 
incidence in other myeloid malignancies remains less investigated, although it is clear the 
predominantly connection of this mutation to de novo AML cases. Recent investigations 
have tried to address in more detailed way the relevance of NPMc+ mutation to other 
myeloid disorders, as secondary AML (sAML) deriving from MDS or chronic phase of 
myeloproliferative disorders (MPD). Interestingly, Zhang and colleagues have reported 
occurrence of NPMc+ mutation in primary MDS cases with an incidence of 5.2% (Zhang 
et al, 2006). This recent finding confers additional value to our observation of MDS cases 
associated to NPMc+ expression in our murine model, underlining the capability of our 
model system to recapitulate main pathological consequences of the NPMc+ expression 
into the hematopoietic compartment. Additional study by Schnittger and colleagues tried to 
address the relevance of NPMc+ in myeloid disease progression by back-tracking NPMc+ 
mutation state at diagnosis of MDS or MPD cases and at the time of progression in the 
leukaemic phase (Schnittger et al, 2011). This study suggests that NPMc+ can be present at 
diagnosis of MDS or MPN or can emerge later during the follow-up of the disease in 
addition or in parallel with other molecular or cytogenetic alterations. This supports the 
idea of a multistep transforming process from MDS or MPD to s-AML and suggests that 
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NPMc+ is not only a key factor in the initiation of de novo AML but may contribute to 
MDS or MPD and its progression to sAML (Dohner et al, 2005). Additional evidences 
suggesting a role of NPMc+ mutations during pre-leukaemic lesion, as myelodysplastic 
syndrome, come from another recent paper reporting a novel NPMc+ conditional mouse 
model (Sportoletti et al, 2013). In this model, the NPMc+ cDNA is inserted into the 
Rosa26 locus and the CAG promoter drives the expression of the mutated protein. To 
induce expression of the mutated protein, NPMc+ mice were crossed with Mx-Cre mice 
and double transgenic animals were treated with pIpC to induced Cre expression followed 
by recombination at loxP sites. This model shares similar genetic design with our system. 
Both Hprt and Rosa26 locus are characterized by open chromatin structure and can 
guarantee transgene expression while avoiding the drawbacks of random insertion, 
transgene silencing, and the deregulation of neighboring genes, making them widely used 
for the generation of knock-in mouse model. Remarkably, Sportoletti’s model does not 
develop leukaemia late in life but displays megakaryocytes expansion and block of 
differentiation, which mirror some of the dysplastic features in the megakaryocytes series 
found in the bone marrow samples from human NPMc+ AML patients (Sportoletti et al, 
2013). Therefore, also this model suggests a possible involvement of NPMc+ mutation in 
inducing myelodysplastic features, which in human frequently represents a pre-leukaemic 
phase (Heaney, 1999). Although genetic similarity between our and Spartoletti’s model, two 
different main phenotypes have been reported. A likely explanation for this divergence may 
be the presence of a cooperating event for leukaemia development such as the hyper-
proliferation induced thought bone marrow transplantation in our system. Indeed, our 
results show that bone marrow transplantation cooperates for leukaemia onset in NPMc+ 
driven leukemogenesis (acceleration of leukaemia development and increased penetrance 
upon serial transplantation experiment).  
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Altogether these observations support the reliability of our system and its value as platform 
to study the pathogenesis of the NPMc+ dependent leukaemia in vivo. However, the 
leukaemia onset in our model is characterized by a long latency and low penetrance. This 
data are consistent with another recently published NPMc+ knock-in mouse model 
(Vassiliou et al, 2011). Vassiliou’s mouse model is of particular interest as it entirely mimics 
the genetic lesion that human patients harbour. The conditional allele was designed into the 
native murine NPM locus, hence, mice expressed only one copy of the wild type NPM 
protein and one mutant protein driven by the same endogenous promoter. Also, in this 
case mice developed leukaemia late in life with a low penetrance (about 30% of the 
animals) and about 50% of the leukaemia were bi-phenotypic (B/myeloid). The long 
latency and low penetrance suggest that NPMc+ needs additional mutations to support a 
full leukaemia phenotype, and that not all the animals acquire such mutations during their 
life span. Indeed, in the same paper, Vassiliou et al. also investigated the occurrence of 
cooperative mutations through transposon insertional mutagenesis. Among others, 
mutations in the Flt3 gene have been selected; however, under their experimental 
conditions, they isolated Flt3 mutations both in NPMc+ and WT mice, thus leaving open 
the question if FLT3 and NPM mutations significantly cooperate in leukaemia 
development. To address this issue we have crossed our NPMc+ model with a constitutive 
knock-in FLT3-ITD mouse model (Lee et al, 2007). FLT3-ITD animals have been shown 
to develop myeloproliferative disorder that did not progress to leukaemia. NPMc+/FLT3-
ITD mice, instead, developed leukaemia very rapidly. Strikingly, all the NPMc+/FLT3-
ITD mice died of leukaemia between 35 and 147 days with a median survival of 72 days. 
Our data demonstrate that NPMc+ and FLT3-ITD mutations cooperating powerfully in 
inducing AMLs in mice. This finding is even more remarkable in light of the kinetic of 
leukaemia development in NPMc+/FLT3-ITD animals compared to the relatively 
moderate effects on murine haematopoiesis that mice bearing only one of the two 
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mutations showed. The extremely rapid onset of disease would suggest that NPMc+ and 
FLT3-ITD mutations when combined are enough to initiate and promote 
leukaemogenesis. Alternatively, FLT3-ITD mutation provides proliferation and survival 
signalling that increase the occurrence of cooperating mutations. The whole genomic 
sequencing of NPMc+ and NPMc+/FLT3-ITD leukaemia should help in verifying these 
alternative hypotheses. It has been proposed that AML is the consequence of the 
cooperation of two functional classes of mutations: class I mutations, conferring a 
proliferative and/or survival advantage, and class II mutations, which impair hematopoietic 
differentiation and/or self renewal proprieties of the stem cell progenitors (Haferlach, 
2008), (Welch et al, 2012). Our murine model strongly supports this hypothesis with 
NPMc+ being the initiating event that confers clonal advantage and FLT3-ITD a strong 
cooperating mutation. It will be intriguing to verify whether NPMc+ acts synergistically 
also with other recurrent mutations associated to NPMc+AML, as DNMT3A or IDH1 
(Takahashi, 2011). 
A major challenge for this study is to identify critical mechanisms imposed by the NPMc+ 
oncogene activation on the normal haematopoiesis and that could count for the 
establishment of the malignant clone and the leukaemia development. Because tumours 
can be considered as hierarchically organized tissues, it has been proposed that, a subset of 
cells with analogous properties of normal stem cells (SC) is responsible for the sustenance 
of the malignant cellular mass (Reya et al, 2001) (Shipitsin & Polyak, 2008). This 
observation has been postulated in the cancer stem cell theory. The strong similarity 
between normal and cancer stem cell makes reasonable to proposed that CSC derived from 
transforming events in the pool of normal stem cell, or by the aberrant acquisition of stem 
cell proprieties in progenitor subset (Tan et al, 2006). Therefore, one of the first 
possibilities that we investigated was whether NPMc+ expression affects the biology of the 
HSCP compartment during the pre-leukemic phases. This investigation has allowed us to 
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make several important observations. Our data show that the expression of the NPMc+ 
oncogene in HSPC compartment expands the most undifferentiated haematopoietic pool, 
and in particular the LT-HSC fraction. We found that one of the putative mechanisms 
responsible for this expansion is an increased proliferation rate in the entire LKS 
compartment. Interestingly, despite we did not observe any difference in MPP cell number, 
we detected also in this population a higher BrdU incorporation rate. This apparent 
discrepancy could be explained considering additional contribution of NPMc+ mutant 
protein on survival pathways (e.g. increased apoptosis) or, alternatively, NPMc+ expression 
may influence the differentiation process in the progenitor compartment. Indeed, we have 
observed a significant increased number of mature myeloid cell (MAC1+/GR1+) cells 
both in the bone marrow and in the spleen of NPMc+ animals (data not shown). 
The replicative history of the HSCs correlates to their biological properties and in 
particular to their self-renewal ability (Orford & Scadden, 2008; Wilson et al, 2008). Indeed, 
the hyper proliferation imposed by serial transplantation results in the premature functional 
exhaustion of the initial HSCs pool (Kamminga et al, 2005). The cellular signal that 
controls the rounds of HSCs replication is probably related to a progressive accumulation 
of DNA damage in the cell (Viale et al, 2009). In a recent study Trumpp and colleagues 
demonstrated the existence of highly quiescent SCs (dormant stem cells) among immune-
phenotypically identical but actively cycling HSCs (Wilson, 2008). Importantly, this 
dormant population is shown to possess the highest self-renewal potential and is essential 
to replenish the haematopoietic system upon stress and injury, thus preventing HSC 
exhaustion. The hypothesis is that dormancy is the mechanism through which HSCs 
preserve their self-renewal potential. Our 5-FU experiments in mice 4 months after BMT 
strongly suggest that despite the increased proliferative rate in the NPMc+ expressing 
HSCs compartment, not only they were not loosing their self-renewal abilities, but they 
showed an expanded capacity of repopulating the haematopoietic compartment upon 
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ablation. This results can be explain both by the expansion of the quiescent HSCs pool or 
by an extended self renewal abilities. The latter is an important acquired feature of cancer 
stem cells (CSC). As we found the pool of HSC expanded, we asked whether NPMc+ is 
able to expand also the replicative potential of the HSCs. The gold-standard experiment to 
test if the HSC pool displays enhanced self-renewal abilities is the in vivo serial 
transplantation assay (Viale et al, 2009). In our experimental setting, this assay ended up 
with an accelerated and full penetrant leukemogenesis in animals expressing NPMc+. This 
result prevented any conclusion about a putative NPMc+ dependent extended self-renewal, 
however, allowed us to conclude that the increased proliferation of the HSC compartment 
imposed by serial round of repopulation of the haematopoietic compartment is, per se, a 
cooperating mechanism of leukemogenesis in vivo. The molecular mechanism underling this 
cooperation needs to be explored but it could be related to the reported oncogene 
associated replicative DNA damage (Di Micco et al, 2006), thus leading to an increased rate 
of mutations in cooperative genes. Also in this case, whole-genome sequencing of theses 
leukaemia would help in understanding if the mutation rate had increased. Moreover, 
although indirectly, these data suggest that the increased proliferation rate imposed by 
NPMc+ in the HSCs compartment may be one of the mechanisms by which NPMc+ 
promote leukaemia. Going back to our original question about the possibility that NPMc+ 
could expand the proliferative potential of the HSCs, the in vitro serial replanting assay 
indicate that NPMc+ HSPC cells do not enhance their replicative potential that exhausts at 
the same rate as control cells. This in vitro data is further supported by the observation that 
when we analysed the HSPC compartment in mice at a later time point (8 months post 
BMT) we found an attenuation of the LT-HSC expansion and, in same cases, even a 
reversion of this phenotype with a reduction of the number of LT-HSCs (data not shown). 
These data suggest that NPMc+ is not able to enhance the number of cell divisions that a 
normal HSC can perform during its life span. Interestingly, as we reported in the results 
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section, we found two cases of MDS in the NPMc+ cohort of mice. MDS is a group of 
disorders in which the HSCs are defective and undergo to functional exhaustion resulting 
in few and poorly functioning blood cells (Pang et al, 2013). Therefore, we can hypothesize 
that the in the MDS mice (that notably died by severe anaemia) we experienced a 
progressive loss of self-renewal ability of the HSCs due to an abnormal proliferative rate. 
Based on the reported results, we can start to depict a scenario about the effect of NPMc+ 
on the normal haematopoietic compartment and the underling mechanisms leading to 
leukaemia development. NPMc+ expands the pool of fully functioning HSCs, however, 
the higher proliferative rate may eventually causes a progressive depletion of the HSC 
compartment leading to bone marrow failure syndromes. Stochastically, the higher 
proliferative rate (maybe in combination with other NPMc+ cellular activities) favours the 
selection of mutations in cooperating genes that eventually expand the HSCs cell renewal 
activity further promoting the selection of a starting leukemic clone. 
In this scenery it would be interesting to understand which is the contribution of FLT3-
ITD mutations to leukaemia development. In a recent paper Chu et al. investigated the 
impact of this mutation to the HSPC through the characterization of a knock-in mouse 
model (Chu, 2012). They reported that physiological expression of FLT3-ITD mutation 
results in changes in the HSPC composition, with reduction of the LT-HSC sub-fraction 
associated to an increase in the proliferation rate. In accordance to the depletion of the 
more primitive stem compartment, they found functional defects in haematopoietic 
reconstitution capacity of FLT3-ITD BM cells. These data suggest that the putative 
mechanism of leukemiogeneis sustained by FLT3-ITD is the increased proliferative rate of 
the HSPC. Therefore, it is suggested that FLT3-ITD mutations do not conferred extended 
self-renewal, but act in a pathway similar to the one that we described for the NPMc+ 
oncogene. On the other hand, our data still suggest that NPMc+ transformation is 
favoured by abnormal proliferation as it is suggested by acceleration of leukaemia onset in 
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serial NPMc+ BMT mice. Thus, it seems that, the strong cooperation between NPMc+ 
and FLT3-ITD mutations could not be explained with a contribution of FLT3-ITD in 
enhancing the self-renewal potential of HSPC. However, it could not be excluded that the 
two mutations together acquire novel functions. Dissecting the molecular mechanisms of 
the powerfully cooperating potential of NPMc+ and FLT3-ITD mutations would give 
valuable insight into our knowledge of the leukaemia pathogenesis. 
 
                                                                                                                      
84	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8. Bibliography 	   	  
                                                                                                                 BIBLIOGRAPHY 
 
85	  
Ablain	  J,	  Nasr	  R,	  Zhu	  J,	  Bazarbachi	  A,	  Lallemand-­‐Breittenbach	  V,	  de	  The	  H	  (2013)	  How	   animal	  models	   of	   leukaemias	   have	   already	   benefited	   patients.	  Mol	  Oncol	  7:	  224-­‐231	  	  Ahn	   JY,	   Liu	   X,	   Cheng	   D,	   Peng	   J,	   Chan	   PK,	   Wade	   PA,	   Ye	   K	   (2005)	  Nucleophosmin/B23,	  a	  nuclear	  PI(3,4,5)P(3)	  receptor,	  mediates	  the	  antiapoptotic	  actions	  of	  NGF	  by	  inhibiting	  CAD.	  Mol	  Cell	  18:	  435-­‐445	  	  Akamine	  R,	  Yamamoto	  T,	  Watanabe	  M,	  Yamazaki	  N,	  Kataoka	  M,	  Ishikawa	  M,	  Ooie	  T,	  Baba	  Y,	  Shinohara	  Y	  (2007)	  Usefulness	  of	  the	  5'	  region	  of	  the	  cDNA	  encoding	  acidic	  ribosomal	   phosphoprotein	   P0	   conserved	   among	   rats,	   mice,	   and	   humans	   as	   a	  standard	   probe	   for	   gene	   expression	   analysis	   in	   different	   tissues	   and	   animal	  species.	  J	  Biochem	  Biophys	  Methods	  70:	  481-­‐486	  	  Akashi	  K,	  Kondo	  M,	  Cheshier	  S,	  Shizuru	  J,	  Gandy	  K,	  Domen	  J,	  Mebius	  R,	  Traver	  D,	  Weissman	   IL	   (1999)	   Lymphoid	   development	   from	   stem	   cells	   and	   the	   common	  lymphocyte	  progenitors.	  Cold	  Spring	  Harb	  Symp	  Quant	  Biol	  64:	  1-­‐12	  	  Albiero	  E,	  Madeo	  D,	  Bolli	  N,	  Giaretta	  I,	  Bona	  ED,	  Martelli	  MF,	  Nicoletti	  I,	  Rodeghiero	  F,	   Falini	   B	   (2007)	   Identification	   and	   functional	   characterization	   of	   a	   cytoplasmic	  nucleophosmin	   leukaemic	  mutant	  generated	  by	  a	  novel	  exon-­‐11	  NPM1	  mutation.	  
Leukemia	  21:	  1099-­‐1103	  	  Alcalay	   M,	   Tiacci	   E,	   Bergomas	   R,	   Bigerna	   B,	   Venturini	   E,	   Minardi	   SP,	   Meani	   N,	  Diverio	  D,	  Bernard	  L,	  Tizzoni	  L,	  Volorio	  S,	  Luzi	  L,	  Colombo	  E,	  Lo	  Coco	  F,	  Mecucci	  C,	  Falini	   B,	   Pelicci	   PG	   (2005)	   Acute	   myeloid	   leukemia	   bearing	   cytoplasmic	  nucleophosmin	   (NPMc+	   AML)	   shows	   a	   distinct	   gene	   expression	   profile	  characterized	  by	  up-­‐regulation	  of	  genes	   involved	  in	  stem-­‐cell	  maintenance.	  Blood	  
106:	  899-­‐902	  	  Alexopoulou	   AN,	   Couchman	   JR,	   Whiteford	   JR	   (2008)	   The	   CMV	   early	  enhancer/chicken	   beta	   actin	   (CAG)	   promoter	   can	   be	   used	   to	   drive	   transgene	  expression	  during	  the	  differentiation	  of	  murine	  embryonic	  stem	  cells	  into	  vascular	  progenitors.	  BMC	  Cell	  Biol	  9:	  2	  	  Alharbi	  RA,	  Pettengell	  R,	  Pandha	  HS,	  Morgan	  R	   (2013)	  The	   role	  of	  HOX	  genes	   in	  normal	  hematopoiesis	  and	  acute	  leukemia.	  Leukemia	  27:	  1000-­‐1008	  	  Becker	  AJ,	  Mc	  CE,	  Till	  JE	  (1963)	  Cytological	  demonstration	  of	  the	  clonal	  nature	  of	  spleen	  colonies	  derived	  from	  transplanted	  mouse	  marrow	  cells.	  Nature	  197:	  452-­‐454	  	  Bertwistle	  D,	  Sugimoto	  M,	  Sherr	  CJ	  (2004)	  Physical	  and	  functional	   interactions	  of	  the	  Arf	  tumor	  suppressor	  protein	  with	  nucleophosmin/B23.	  Mol	  Cell	  Biol	  24:	  985-­‐996	  	  Biggiogera	   M,	   Fakan	   S,	   Kaufmann	   SH,	   Black	   A,	   Shaper	   JH,	   Busch	   H	   (1989)	  Simultaneous	   immunoelectron	  microscopic	   visualization	   of	   protein	  B23	   and	  C23	  distribution	  in	  the	  HeLa	  cell	  nucleolus.	  J	  Histochem	  Cytochem	  37:	  1371-­‐1374	  
                                                                                                                 BIBLIOGRAPHY 
 
86	  
	  Boissel	  N,	  Renneville	  A,	  Biggio	  V,	  Philippe	  N,	  Thomas	  X,	  Cayuela	  JM,	  Terre	  C,	  Tigaud	  I,	  Castaigne	  S,	  Raffoux	  E,	  De	  Botton	  S,	  Fenaux	  P,	  Dombret	  H,	  Preudhomme	  C	  (2005)	  Prevalence,	  clinical	  profile,	  and	  prognosis	  of	  NPM	  mutations	   in	  AML	  with	  normal	  karyotype.	  Blood	  106:	  3618-­‐3620	  	  Bonetti	  P,	  Davoli	  T,	  Sironi	  C,	  Amati	  B,	  Pelicci	  PG,	  Colombo	  E	  (2008)	  Nucleophosmin	  and	   its	  AML-­‐associated	  mutant	   regulate	   c-­‐Myc	   turnover	   through	  Fbw7	  gamma.	   J	  
Cell	  Biol	  182:	  19-­‐26	  	  Borer	  RA,	  Lehner	  CF,	  Eppenberger	  HM,	  Nigg	  EA	  (1989)	  Major	  nucleolar	  proteins	  shuttle	  between	  nucleus	  and	  cytoplasm.	  Cell	  56:	  379-­‐390	  	  Borrow	   J,	  Shearman	  AM,	  Stanton	  VP,	   Jr.,	  Becher	  R,	  Collins	  T,	  Williams	  AJ,	  Dube	   I,	  Katz	  F,	  Kwong	  YL,	  Morris	  C,	  Ohyashiki	  K,	  Toyama	  K,	  Rowley	  J,	  Housman	  DE	  (1996)	  The	  t(7;11)(p15;p15)	  translocation	  in	  acute	  myeloid	  leukaemia	  fuses	  the	  genes	  for	  nucleoporin	  NUP98	  and	  class	  I	  homeoprotein	  HOXA9.	  Nat	  Genet	  12:	  159-­‐167	  	  Bos	  JL,	  Toksoz	  D,	  Marshall	  CJ,	  Verlaan-­‐de	  Vries	  M,	  Veeneman	  GH,	  van	  der	  Eb	  AJ,	  van	  Boom	  JH,	  Janssen	  JW,	  Steenvoorden	  AC	  (1985)	  Amino-­‐acid	  substitutions	  at	  codon	  13	  of	  the	  N-­‐ras	  oncogene	  in	  human	  acute	  myeloid	  leukaemia.	  Nature	  315:	  726-­‐730	  	  Boyd	  MT,	  Vlatkovic	  N,	  Haines	  DS	  (2000)	  A	  novel	  cellular	  protein	  (MTBP)	  binds	  to	  MDM2	   and	   induces	   a	   G1	   arrest	   that	   is	   suppressed	   by	   MDM2.	   J	   Biol	   Chem	   275:	  31883-­‐31890	  	  Brady	  SN,	  Yu	  Y,	  Maggi	  LB,	  Jr.,	  Weber	  JD	  (2004)	  ARF	  impedes	  NPM/B23	  shuttling	  in	  an	  Mdm2-­‐sensitive	  tumor	  suppressor	  pathway.	  Mol	  Cell	  Biol	  24:	  9327-­‐9338	  	  Bullinger	   L,	   Dohner	   K,	   Bair	   E,	   Frohling	   S,	   Schlenk	   RF,	   Tibshirani	   R,	   Dohner	   H,	  Pollack	   JR	   (2004)	   Use	   of	   gene-­‐expression	   profiling	   to	   identify	   prognostic	  subclasses	  in	  adult	  acute	  myeloid	  leukemia.	  N	  Engl	  J	  Med	  350:	  1605-­‐1616	  	  Caligiuri	  MA,	  Schichman	  SA,	  Strout	  MP,	  Mrozek	  K,	  Baer	  MR,	  Frankel	  SR,	  Barcos	  M,	  Herzig	  GP,	  Croce	  CM,	  Bloomfield	  CD	  (1994)	  Molecular	  rearrangement	  of	  the	  ALL-­‐1	  gene	   in	   acute	   myeloid	   leukemia	   without	   cytogenetic	   evidence	   of	   11q23	  chromosomal	  translocations.	  Cancer	  Res	  54:	  370-­‐373	  	  Castilla	  LH,	  Garrett	  L,	  Adya	  N,	  Orlic	  D,	  Dutra	  A,	  Anderson	  S,	  Owens	   J,	  Eckhaus	  M,	  Bodine	   D,	   Liu	   PP	   (1999)	   The	   fusion	   gene	   Cbfb-­‐MYH11	   blocks	   myeloid	  differentiation	   and	   predisposes	   mice	   to	   acute	   myelomonocytic	   leukaemia.	   Nat	  
Genet	  23:	  144-­‐146	  	  Caudill	  JS,	  Sternberg	  AJ,	  Li	  CY,	  Tefferi	  A,	  Lasho	  TL,	  Steensma	  DP	  (2006)	  C-­‐terminal	  nucleophosmin	   mutations	   are	   uncommon	   in	   chronic	   myeloid	   disorders.	   Br	   J	  
Haematol	  133:	  638-­‐641	  	  Chan	  IT,	  Kutok	  JL,	  Williams	  IR,	  Cohen	  S,	  Kelly	  L,	  Shigematsu	  H,	  Johnson	  L,	  Akashi	  K,	  Tuveson	  DA,	   Jacks	  T,	  Gilliland	  DG	   (2004)	  Conditional	   expression	  of	  oncogenic	  K-­‐
                                                                                                                 BIBLIOGRAPHY 
 
87	  
ras	   from	   its	   endogenous	   promoter	   induces	   a	   myeloproliferative	   disease.	   J	   Clin	  
Invest	  113:	  528-­‐538	  	  Chang	   JH,	   Lin	   JY,	   Wu	   MH,	   Yung	   BY	   (1998)	   Evidence	   for	   the	   ability	   of	  nucleophosmin/B23	  to	  bind	  ATP.	  Biochem	  J	  329	  (	  Pt	  3):	  539-­‐544	  	  Chang	   JH,	  Olson	  MO	  (1990)	  Structure	  of	   the	  gene	   for	  rat	  nucleolar	  protein	  B23.	   J	  
Biol	  Chem	  265:	  18227-­‐18233	  	  Colombo	  E,	  Alcalay	  M,	  Pelicci	  PG	  (2011)	  Nucleophosmin	  and	  its	  complex	  network:	  a	  possible	  therapeutic	  target	  in	  hematological	  diseases.	  Oncogene	  30:	  2595-­‐2609	  	  Colombo	  E,	  Bonetti	  P,	  Lazzerini	  Denchi	  E,	  Martinelli	  P,	  Zamponi	  R,	  Marine	  JC,	  Helin	  K,	   Falini	   B,	   Pelicci	   PG	   (2005)	   Nucleophosmin	   is	   required	   for	   DNA	   integrity	   and	  p19Arf	  protein	  stability.	  Mol	  Cell	  Biol	  25:	  8874-­‐8886	  	  Colombo	   E,	   Marine	   JC,	   Danovi	   D,	   Falini	   B,	   Pelicci	   PG	   (2002)	   Nucleophosmin	  regulates	  the	  stability	  and	  transcriptional	  activity	  of	  p53.	  Nat	  Cell	  Biol	  4:	  529-­‐533	  	  den	  Besten	  W,	  Kuo	  ML,	  Williams	  RT,	  Sherr	  CJ	  (2005)	  Myeloid	  leukemia-­‐associated	  nucleophosmin	  mutants	  perturb	  p53-­‐dependent	  and	  independent	  activities	  of	  the	  Arf	  tumor	  suppressor	  protein.	  Cell	  Cycle	  4:	  1593-­‐1598	  	  Dergunova	  N,	  Bulycheva	  TI,	  Artemenko	  EG,	  Shpakova	  AP,	  Pegova	  AN,	  Gemjian	  EG,	  Dudnik	  OA,	  Zatsepina	  OV,	  Malashenko	  OS	  (2002)	  A	  major	  nucleolar	  protein	  B23	  as	  a	  marker	  of	  proliferation	  activity	  of	  human	  peripheral	  lymphocytes.	  Immunol	  Lett	  
83:	  67-­‐72	  	  Dhar	   SK,	   St	   Clair	  DK	   (2009)	  Nucleophosmin	   blocks	  mitochondrial	   localization	   of	  p53	  and	  apoptosis.	  J	  Biol	  Chem	  284:	  16409-­‐16418	  	  Di	   Micco	   R,	   Fumagalli	   M,	   Cicalese	   A,	   Piccinin	   S,	   Gasparini	   P,	   Luise	   C,	   Schurra	   C,	  Garre	   M,	   Nuciforo	   PG,	   Bensimon	   A,	   Maestro	   R,	   Pelicci	   PG,	   d'Adda	   di	   Fagagna	   F	  (2006)	  Oncogene-­‐induced	  senescence	  is	  a	  DNA	  damage	  response	  triggered	  by	  DNA	  hyper-­‐replication.	  Nature	  444:	  638-­‐642	  
 Doetschman	  T,	  Gregg	  RG,	  Maeda	  N,	  Hooper	  ML,	  Melton	  DW,	  Thompson	  S,	  Smithies	  O, (1987)	  Targetted	  correction	  of	  a	  mutant	  HPRT	  gene	  in	  mouse	  embryonic	  stem	  cells.	  Nature	  330:	  576-­‐578	  
 Dohner	  H	  (2007)	  Implication	  of	  the	  molecular	  characterization	  of	  acute	  myeloid	  leukemia.	  Hematology	  Am	  Soc	  Hematol	  Educ	  Program:	  412-­‐419	  	  Dohner	  K,	  Schlenk	  RF,	  Habdank	  M,	  Scholl	  C,	  Rucker	  FG,	  Corbacioglu	  A,	  Bullinger	  L,	  Frohling	   S,	   Dohner	   H	   (2005)	   Mutant	   nucleophosmin	   (NPM1)	   predicts	   favorable	  prognosis	  in	  younger	  adults	  with	  acute	  myeloid	  leukemia	  and	  normal	  cytogenetics:	  interaction	  with	  other	  gene	  mutations.	  Blood	  106:	  3740-­‐3746	  	  
                                                                                                                 BIBLIOGRAPHY 
 
88	  
Dominguez-­‐Sola	  D,	  Ying	  CY,	  Grandori	  C,	  Ruggiero	  L,	  Chen	  B,	  Li	  M,	  Galloway	  DA,	  Gu	  W,	  Gautier	  J,	  Dalla-­‐Favera	  R	  (2007)	  Non-­‐transcriptional	  control	  of	  DNA	  replication	  by	  c-­‐Myc.	  Nature	  448:	  445-­‐451	  	  Ernst	   T,	   Chase	   A,	   Zoi	   K,	  Waghorn	   K,	   Hidalgo-­‐Curtis	   C,	   Score	   J,	   Jones	   A,	   Grand	   F,	  Reiter	   A,	   Hochhaus	   A,	   Cross	   NC	   (2010)	   Transcription	   factor	   mutations	   in	  myelodysplastic/myeloproliferative	  neoplasms.	  Haematologica	  95:	  1473-­‐1480	  	  Estey	  E,	  Dohner	  H	  (2006)	  Acute	  myeloid	  leukaemia.	  Lancet	  368:	  1894-­‐1907	  	  Estey	  EH	   (2013)	  Acute	  myeloid	   leukemia:	  2013	  update	  on	   risk-­‐stratification	  and	  management.	  Am	  J	  Hematol	  88:	  318-­‐327	  	  Falini	  B,	  Bolli	  N,	  Shan	  J,	  Martelli	  MP,	  Liso	  A,	  Pucciarini	  A,	  Bigerna	  B,	  Pasqualucci	  L,	  Mannucci	  R,	  Rosati	  R,	  Gorello	  P,	  Diverio	  D,	  Roti	  G,	  Tiacci	  E,	  Cazzaniga	  G,	  Biondi	  A,	  Schnittger	  S,	  Haferlach	  T,	  Hiddemann	  W,	  Martelli	  MF,	  Gu	  W,	  Mecucci	  C,	  Nicoletti	  I	  (2006)	  Both	   carboxy-­‐terminus	  NES	  motif	   and	  mutated	   tryptophan(s)	   are	   crucial	  for	   aberrant	  nuclear	   export	   of	   nucleophosmin	   leukemic	  mutants	   in	  NPMc+	  AML.	  
Blood	  107:	  4514-­‐4523	  	  Falini	   B,	   Martelli	   MP,	   Bolli	   N,	   Sportoletti	   P,	   Liso	   A,	   Tiacci	   E,	   Haferlach	   T	   (2011)	  Acute	   myeloid	   leukemia	   with	   mutated	   nucleophosmin	   (NPM1):	   is	   it	   a	   distinct	  entity?	  Blood	  117:	  1109-­‐1120	  	  Falini	  B,	  Mecucci	  C,	  Tiacci	  E,	  Alcalay	  M,	  Rosati	  R,	  Pasqualucci	  L,	  La	  Starza	  R,	  Diverio	  D,	  Colombo	  E,	  Santucci	  A,	  Bigerna	  B,	  Pacini	  R,	  Pucciarini	  A,	  Liso	  A,	  Vignetti	  M,	  Fazi	  P,	  Meani	   N,	   Pettirossi	   V,	   Saglio	   G,	  Mandelli	   F,	   Lo-­‐Coco	   F,	   Pelicci	   PG,	  Martelli	  MF	  (2005)	  Cytoplasmic	  nucleophosmin	  in	  acute	  myelogenous	  leukemia	  with	  a	  normal	  karyotype.	  N	  Engl	  J	  Med	  352:	  254-­‐266	  	  Falini	  B,	  Nicoletti	  I,	  Martelli	  MF,	  Mecucci	  C	  (2007)	  Acute	  myeloid	  leukemia	  carrying	  cytoplasmic/mutated	  nucleophosmin	  (NPMc+	  AML):	  biologic	  and	  clinical	  features.	  
Blood	  109:	  874-­‐885	  	  Fankhauser	   C,	   Izaurralde	   E,	   Adachi	   Y,	   Wingfield	   P,	   Laemmli	   UK	   (1991)	   Specific	  complex	  of	  human	  immunodeficiency	  virus	  type	  1	  rev	  and	  nucleolar	  B23	  proteins:	  dissociation	  by	  the	  Rev	  response	  element.	  Mol	  Cell	  Biol	  11:	  2567-­‐2575	  	  
Fey	  M,	  Dreyling	  M,	  (2009)	  Acute	  myeloblastic	  leukemia	  in	  adult	  patients:	  ESMO	  clinical	  recommendations	  for	  diagnosis,	  treatment	  and	  follow-­‐up.	  Ann	  Oncol	  20	  S4:100-­‐1	  	  Feuerstein	  N,	  Mond	  JJ	  (1987)	  "Numatrin,"	  a	  nuclear	  matrix	  protein	  associated	  with	  induction	  of	  proliferation	  in	  B	  lymphocytes.	  J	  Biol	  Chem	  262:	  11389-­‐11397	  	  Fidler	   IJ	   (2012)	   Biological	   heterogeneity	   of	   cancer:	   implication	   to	   therapy.	  Hum	  
Vaccin	  Immunother	  8:	  1141-­‐1142	  	  
                                                                                                                 BIBLIOGRAPHY 
 
89	  
Frehlick	   LJ,	   Eirin-­‐Lopez	   JM,	   Ausio	   J	   (2007)	   New	   insights	   into	   the	  nucleophosmin/nucleoplasmin	  family	  of	  nuclear	  chaperones.	  Bioessays	  29:	  49-­‐59	  	  Frohling	   S,	   Schlenk	   RF,	   Breitruck	   J,	   Benner	   A,	   Kreitmeier	   S,	   Tobis	   K,	   Dohner	   H,	  Dohner	  K	  (2002)	  Prognostic	  significance	  of	  activating	  FLT3	  mutations	  in	  younger	  adults	   (16	   to	  60	   years)	  with	   acute	  myeloid	   leukemia	   and	  normal	   cytogenetics:	   a	  study	  of	  the	  AML	  Study	  Group	  Ulm.	  Blood	  100:	  4372-­‐4380	  	  Geyer	  RK,	   Yu	  ZK,	  Maki	  CG	   (2000)	  The	  MDM2	  RING-­‐finger	  domain	   is	   required	   to	  promote	  p53	  nuclear	  export.	  Nat	  Cell	  Biol	  2:	  569-­‐573	  	  Gilliland	  DG,	  Griffin	  JD	  (2002)	  Role	  of	  FLT3	  in	  leukemia.	  Curr	  Opin	  Hematol	  9:	  274-­‐281	  	  Goodell	   MA,	   Brose	   K,	   Paradis	   G,	   Conner	   AS,	   Mulligan	   RC	   (1996)	   Isolation	   and	  functional	   properties	   of	   murine	   hematopoietic	   stem	   cells	   that	   are	   replicating	   in	  vivo.	  J	  Exp	  Med	  183:	  1797-­‐1806	  	  Grisendi	   S,	   Bernardi	   R,	   Rossi	   M,	   Cheng	   K,	   Khandker	   L,	   Manova	   K,	   Pandolfi	   PP	  (2005)	   Role	   of	   nucleophosmin	   in	   embryonic	   development	   and	   tumorigenesis.	  
Nature	  437:	  147-­‐153	  	  Grisendi	  S,	  Mecucci	  C,	  Falini	  B,	  Pandolfi	  PP	  (2006)	  Nucleophosmin	  and	  cancer.	  Nat	  
Rev	  Cancer	  6:	  493-­‐505	  	  Gruszka	   AM,	   Lavorgna	   S,	   Consalvo	   MI,	   Ottone	   T,	   Martinelli	   C,	   Cinquanta	   M,	  Ossolengo	  G,	  Pruneri	  G,	  Buccisano	  F,	  Divona	  M,	  Cedrone	  M,	  Ammatuna	  E,	  Venditti	  A,	   de	   Marco	   A,	   Lo-­‐Coco	   F,	   Pelicci	   PG	   (2010)	   A	   monoclonal	   antibody	   against	  mutated	  nucleophosmin	  1	  for	  the	  molecular	  diagnosis	  of	  acute	  myeloid	  leukemias.	  
Blood	  116:	  2096-­‐2102	  	  Haferlach	   T	   (2008)	   Molecular	   genetic	   pathways	   as	   therapeutic	   targets	   in	   acute	  myeloid	  leukemia.	  Hematology	  Am	  Soc	  Hematol	  Educ	  Program:	  400-­‐411	  	  Harrison	   DE,	   Lerner	   CP	   (1991)	   Most	   primitive	   hematopoietic	   stem	   cells	   are	  stimulated	   to	   cycle	   rapidly	   after	   treatment	   with	   5-­‐fluorouracil.	  Blood	  78:	   1237-­‐1240	  	  Hayashi	   S,	   McMahon	   AP	   (2002)	   Efficient	   recombination	   in	   diverse	   tissues	   by	   a	  tamoxifen-­‐inducible	   form	   of	   Cre:	   a	   tool	   for	   temporally	   regulated	   gene	  activation/inactivation	  in	  the	  mouse.	  Dev	  Biol	  244:	  305-­‐318	  	  Heaney	   LM,	   Golde	   DW	   (1999)	   Myelodysplasia.	   The	   New	   England	   Journal	   of	  Medicine	  340,21:	  1649-­‐60	  
 Herrera	   JE,	   Correia	   JJ,	   Jones	  AE,	  Olson	  MO	   (1996)	   Sedimentation	   analyses	   of	   the	  salt-­‐	   and	   divalent	   metal	   ion-­‐induced	   oligomerization	   of	   nucleolar	   protein	   B23.	  
Biochemistry	  35:	  2668-­‐2673	  	  
                                                                                                                 BIBLIOGRAPHY 
 
90	  
Herrera	   JE,	   Savkur	   R,	   Olson	   MO	   (1995)	   The	   ribonuclease	   activity	   of	   nucleolar	  protein	  B23.	  Nucleic	  Acids	  Res	  23:	  3974-­‐3979	  	  Hingorani	   K,	   Szebeni	   A,	   Olson	   MO	   (2000)	   Mapping	   the	   functional	   domains	   of	  nucleolar	  protein	  B23.	  J	  Biol	  Chem	  275:	  24451-­‐24457	  	  Ishikawa	  Y,	  Kiyoi	  H,	  Tsujimura	  A,	  Miyawaki	  S,	  Miyazaki	  Y,	  Kuriyama	  K,	  Tomonaga	  M,	  Naoe	  T	  (2009)	  Comprehensive	  analysis	  of	  cooperative	  gene	  mutations	  between	  class	  I	  and	  class	  II	  in	  de	  novo	  acute	  myeloid	  leukemia.	  Eur	  J	  Haematol	  83:	  90-­‐98	  	  Jagus	  R,	   Joshi	  B,	  Barber	  GN	   (1999)	  PKR,	   apoptosis	   and	   cancer.	   Int	   J	  Biochem	  Cell	  
Biol	  31:	  123-­‐138	  	  Jiang	   PS,	   Chang	   JH,	   Yung	   BY	   (2000)	   Different	   kinases	   phosphorylate	  nucleophosmin/B23	  at	  different	  sites	  during	  G(2)	  and	  M	  phases	  of	   the	  cell	   cycle.	  
Cancer	  Lett	  153:	  151-­‐160	  	  Jiang	   PS,	   Yung	   BY	   (1999)	  Down-­‐regulation	   of	   nucleophosmin/B23	  mRNA	  delays	  the	  entry	  of	  cells	  into	  mitosis.	  Biochem	  Biophys	  Res	  Commun	  257:	  865-­‐870	  	  Jordan	  CT,	  Guzman	  ML,	  Noble	  M	  (2006)	  Cancer	  stem	  cells.	  N	  Engl	  J	  Med	  355:	  1253-­‐1261	  	  Kai	  K,	  Arima	  Y,	  Kamiya	  T,	   Saya	  H	   (2010)	  Breast	   cancer	   stem	  cells.	  Breast	  Cancer	  
17:	  80-­‐85	  	  Kamminga	  LM,	  van	  Os	  R,	  Ausema	  A,	  Noach	  EJ,	  Weersing	  E,	  Dontje	  B,	  Vellenga	  E,	  de	  Haan	   G	   (2005)	   Impaired	   hematopoietic	   stem	   cell	   functioning	   after	   serial	  transplantation	  and	  during	  normal	  aging.	  Stem	  Cells	  23:	  82-­‐92	  	  Kang	   YJ,	   Olson	  MO,	   Busch	   H	   (1974)	   Phosphorylation	   of	   acid-­‐soluble	   proteins	   in	  isolated	   nucleoli	   of	   Novikoff	   hepatoma	   ascites	   cells.	   Effects	   of	   divalent	   cations.	   J	  
Biol	  Chem	  249:	  5580-­‐5585	  	  Kelly	  LM,	  Kutok	  JL,	  Williams	  IR,	  Boulton	  CL,	  Amaral	  SM,	  Curley	  DP,	  Ley	  TJ,	  Gilliland	  DG	  (2002a)	  PML/RARalpha	  and	  FLT3-­‐ITD	  induce	  an	  APL-­‐like	  disease	   in	  a	  mouse	  model.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  99:	  8283-­‐8288	  	  Kelly	   LM,	   Liu	   Q,	   Kutok	   JL,	   Williams	   IR,	   Boulton	   CL,	   Gilliland	   DG	   (2002b)	   FLT3	  internal	   tandem	   duplication	   mutations	   associated	   with	   human	   acute	   myeloid	  leukemias	  induce	  myeloproliferative	  disease	  in	  a	  murine	  bone	  marrow	  transplant	  model.	  Blood	  99:	  310-­‐318	  	  Kerr	   LE,	   Birse-­‐Archbold	   JL,	   Short	   DM,	   McGregor	   AL,	   Heron	   I,	   Macdonald	   DC,	  Thompson	  J,	  Carlson	  GJ,	  Kelly	  JS,	  McCulloch	  J,	  Sharkey	  J	  (2007)	  Nucleophosmin	  is	  a	  novel	  Bax	  chaperone	  that	  regulates	  apoptotic	  cell	  death.	  Oncogene	  26:	  2554-­‐2562	  	  
                                                                                                                 BIBLIOGRAPHY 
 
91	  
Kiel	  MJ,	  Yilmaz	  OH,	  Morrison	  SJ	  (2008)	  CD150-­‐	  cells	  are	  transiently	  reconstituting	  multipotent	  progenitors	  with	  little	  or	  no	  stem	  cell	  activity.	  Blood	  111:	  4413-­‐4414;	  author	  reply	  4414-­‐4415	  	  Kondo	   M,	   Weissman	   IL,	   Akashi	   K	   (1997a)	   Identification	   of	   clonogenic	   common	  lymphoid	  progenitors	  in	  mouse	  bone	  marrow.	  Cell	  91:	  661-­‐672	  	  Kondo	  T,	  Minamino	  N,	  Nagamura-­‐Inoue	  T,	  Matsumoto	  M,	  Taniguchi	  T,	  Tanaka	  N	  (1997b)	   Identification	   and	   characterization	   of	   nucleophosmin/B23/numatrin	  which	  binds	  the	  anti-­‐oncogenic	  transcription	  factor	  IRF-­‐1	  and	  manifests	  oncogenic	  activity.	  Oncogene	  15:	  1275-­‐1281	  	  Kosmider	  O,	  Moreau-­‐Gachelin	  F	  (2006)	  From	  mice	  to	  human:	  the	  "two-­‐hit	  model"	  of	  leukemogenesis.	  Cell	  Cycle	  5:	  569-­‐570	  	  Kroon	  E,	  Krosl	   J,	  Thorsteinsdottir	  U,	  Baban	  S,	  Buchberg	  AM,	  Sauvageau	  G	   (1998)	  Hoxa9	  transforms	  primary	  bone	  marrow	  cells	  through	  specific	  collaboration	  with	  Meis1a	  but	  not	  Pbx1b.	  Embo	  J	  17:	  3714-­‐3725	  	  Kurki	  S,	  Peltonen	  K,	  Laiho	  M	  (2004)	  Nucleophosmin,	  HDM2	  and	  p53:	  players	  in	  UV	  damage	  incited	  nucleolar	  stress	  response.	  Cell	  Cycle	  3:	  976-­‐979	  	  Laborda	   J	   (1991)	  36B4	   cDNA	  used	  as	   an	  estradiol-­‐independent	  mRNA	  control	   is	  the	   cDNA	   for	   human	   acidic	   ribosomal	   phosphoprotein	   PO.	  Nucleic	  Acids	  Res	  19:	  3998	  	  Lane	  SW,	  Gilliland	  DG	  (2010)	  Leukemia	  stem	  cells.	  Semin	  Cancer	  Biol	  20:	  71-­‐76	  	  Lapidot	  T,	  Sirard	  C,	  Vormoor	  J,	  Murdoch	  B,	  Hoang	  T,	  Caceres-­‐Cortes	   J,	  Minden	  M,	  Paterson	   B,	   Caligiuri	   MA,	   Dick	   JE	   (1994)	   A	   cell	   initiating	   human	   acute	   myeloid	  leukaemia	  after	  transplantation	  into	  SCID	  mice.	  Nature	  367:	  645-­‐648	  	  Lee	  BH,	  Tothova	  Z,	  Levine	  RL,	  Anderson	  K,	  Buza-­‐Vidas	  N,	  Cullen	  DE,	  McDowell	  EP,	  Adelsperger	   J,	   Frohling	   S,	   Huntly	   BJ,	   Beran	   M,	   Jacobsen	   SE,	   Gilliland	   DG	   (2007)	  FLT3	   mutations	   confer	   enhanced	   proliferation	   and	   survival	   properties	   to	  multipotent	  progenitors	   in	  a	  murine	  model	  of	  chronic	  myelomonocytic	   leukemia.	  
Cancer	  Cell	  12:	  367-­‐380	  	  Leone	  G,	  Sica	  S,	  Ortu	  La	  Barbera	  E,	  Testa	  U,	  Riccioni	  R,	  Labbaye	  C,	  Peschle	  C,	  Zollino	  M	   (1998)	   Secondary	   leukemia	   responsive	   to	   retinoic	   acid	   with	   abnormal	  localization	  of	  RARalpha	  protein:	  a	  report	  of	  two	  cases.	  Blood	  91:	  4811-­‐4812	  	  Li	  D,	  Dobrowolska	  G,	  Krebs	  EG	  (1996)	  The	  physical	  association	  of	  casein	  kinase	  2	  with	  nucleolin.	  J	  Biol	  Chem	  271:	  15662-­‐15668	  	  Li	  J,	  Zhang	  X,	  Sejas	  DP,	  Bagby	  GC,	  Pang	  Q	  (2004)	  Hypoxia-­‐induced	  nucleophosmin	  protects	  cell	  death	  through	  inhibition	  of	  p53.	  J	  Biol	  Chem	  279:	  41275-­‐41279	  	  
                                                                                                                 BIBLIOGRAPHY 
 
92	  
Licht	   JD	   (2001)	   AML1	   and	   the	   AML1-­‐ETO	   fusion	   protein	   in	   the	   pathogenesis	   of	  t(8;21)	  AML.	  Oncogene	  20:	  5660-­‐5679	  	  Liso	  A,	  Bogliolo	  A,	  Freschi	  V,	  Martelli	  MP,	  Pileri	  SA,	  Santodirocco	  M,	  Bolli	  N,	  Martelli	  MF,	   Falini	   B	   (2008)	   In	   human	   genome,	   generation	   of	   a	   nuclear	   export	   signal	  through	   duplication	   appears	   unique	   to	   nucleophosmin	   (NPM1)	  mutations	   and	   is	  restricted	  to	  AML.	  Leukemia	  22:	  1285-­‐1289	  	  Livak	   KJ,	   Schmittgen	   TD	   (2001)	   Analysis	   of	   relative	   gene	   expression	   data	   using	  real-­‐time	  quantitative	  PCR	  and	  the	  2(-­‐Delta	  Delta	  C(T))	  Method.	  Methods	  25:	  402-­‐408	  	  Lowenberg	   B,	   Griffin	   JD,	   Tallman	  MS	   (2003)	   Acute	  myeloid	   leukemia	   and	   acute	  promyelocytic	  leukemia.	  Hematology	  Am	  Soc	  Hematol	  Educ	  Program:	  82-­‐101	  	  Mackarehtschian	  K,	  Hardin	   JD,	  Moore	  KA,	   Boast	   S,	   Goff	   SP,	   Lemischka	   IR	   (1995)	  Targeted	   disruption	   of	   the	   flk2/flt3	   gene	   leads	   to	   deficiencies	   in	   primitive	  hematopoietic	  progenitors.	  Immunity	  3:	  147-­‐161	  	  Magli	   MC,	   Barba	   P,	   Celetti	   A,	   De	   Vita	   G,	   Cillo	   C,	   Boncinelli	   E	   (1991)	   Coordinate	  regulation	  of	  HOX	  genes	  in	  human	  hematopoietic	  cells.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  88:	  6348-­‐6352	  	  Maiguel	  DA,	  Jones	  L,	  Chakravarty	  D,	  Yang	  C,	  Carrier	  F	  (2004)	  Nucleophosmin	  sets	  a	  threshold	  for	  p53	  response	  to	  UV	  radiation.	  Mol	  Cell	  Biol	  24:	  3703-­‐3711	  	  Mardis,	  E.R.,	  Ding,	  L.,	  Dooling,	  D.J.,	  Larson,	  D.E.,	  McLellan,	  M.D.,	  Chen,	  K.,	  Koboldt,	  D.C.,	  Fulton,	  R.S.,	  Delehaunty,	  K.D.,	  McGrath,	  S.D.,	  et	  al.	  (2009).	  Recurring	  mutations	  found	   by	   sequencing	   an	   acute	   myeloid	   leukemia	   genome.	   N.	   Engl.	   J.	   Med.	   361,	  1058–1066.	  	  Mariano	   AR,	   Colombo	   E,	   Luzi	   L,	   Martinelli	   P,	   Volorio	   S,	   Bernard	   L,	   Meani	   N,	  Bergomas	   R,	   Alcalay	   M,	   Pelicci	   PG	   (2006)	   Cytoplasmic	   localization	   of	   NPM	   in	  myeloid	   leukemias	   is	   dictated	   by	   gain-­‐of-­‐function	   mutations	   that	   create	   a	  functional	  nuclear	  export	  signal.	  Oncogene	  25:	  4376-­‐4380	  	  Martelli	  MP,	  Pettirossi	  V,	  Thiede	  C,	  Bonifacio	  E,	  Mezzasoma	  F,	  Cecchini	  D,	  Pacini	  R,	  Tabarrini	  A,	  Ciurnelli	  R,	  Gionfriddo	   I,	  Manes	  N,	  Rossi	  R,	  Giunchi	  L,	  Oelschlagel	  U,	  Brunetti	  L,	  Gemei	  M,	  Delia	  M,	  Specchia	  G,	  Liso	  A,	  Di	  Ianni	  M,	  Di	  Raimondo	  F,	  Falzetti	  F,	  Del	  Vecchio	  L,	  Martelli	  MF,	  Falini	  B	  (2010)	  CD34+	  cells	  from	  AML	  with	  mutated	  NPM1	   harbor	   cytoplasmic	   mutated	   nucleophosmin	   and	   generate	   leukemia	   in	  immunocompromised	  mice.	  Blood	  116:	  3907-­‐3922	  	  Meloni	  G,	  Mancini	  M,	  Gianfelici	  V,	  Martelli	  MP,	  Foa	  R,	  Falini	  B	  (2009)	  Late	  relapse	  of	  acute	  myeloid	  leukemia	  with	  mutated	  NPM1	  after	  eight	  years:	  evidence	  of	  NPM1	  mutation	  stability.	  Haematologica	  94:	  298-­‐300	  	  
                                                                                                                 BIBLIOGRAPHY 
 
93	  
Milne	  TA,	  Briggs	  SD,	  Brock	  HW,	  Martin	  ME,	  Gibbs	  D,	  Allis	  CD,	  Hess	  JL	  (2002)	  MLL	  targets	  SET	  domain	  methyltransferase	  activity	  to	  Hox	  gene	  promoters.	  Mol	  Cell	  10:	  1107-­‐1117	  	  Morris	  SW,	  Kirstein	  MN,	  Valentine	  MB,	  Dittmer	  KG,	  Shapiro	  DN,	  Saltman	  DL,	  Look	  AT	  (1994)	  Fusion	  of	  a	  kinase	  gene,	  ALK,	  to	  a	  nucleolar	  protein	  gene,	  NPM,	  in	  non-­‐Hodgkin's	  lymphoma.	  Science	  263:	  1281-­‐1284	  	  Morrison	   SJ,	   Weissman	   IL	   (1994)	   The	   long-­‐term	   repopulating	   subset	   of	  hematopoietic	  stem	  cells	  is	  deterministic	  and	  isolatable	  by	  phenotype.	  Immunity	  1:	  661-­‐673	  	  Mrozek	   K,	   Heerema	   NA,	   Bloomfield	   CD	   (2004)	   Cytogenetics	   in	   acute	   leukemia.	  
Blood	  Rev	  18:	  115-­‐136	  	  Nakamura	   T	   (2006)	   [Homeobox	   genes	   and	   leukemia:	   the	   role	   of	   HOX-­‐MEIS	  interaction].	  Rinsho	  Ketsueki	  47:	  1423-­‐1430	  	  Nakao	  M,	  Yokota	  S,	  Iwai	  T,	  Kaneko	  H,	  Horiike	  S,	  Kashima	  K,	  Sonoda	  Y,	  Fujimoto	  T,	  Misawa	   S	   (1996)	   Internal	   tandem	   duplication	   of	   the	   flt3	   gene	   found	   in	   acute	  myeloid	  leukemia.	  Leukemia	  10:	  1911-­‐1918	  	  Namboodiri	   VM,	   Akey	   IV,	   Schmidt-­‐Zachmann	  MS,	   Head	   JF,	   Akey	   CW	   (2004)	   The	  structure	   and	   function	   of	   Xenopus	   NO38-­‐core,	   a	   histone	   chaperone	   in	   the	  nucleolus.	  Structure	  12:	  2149-­‐2160	  	  Nishimura	  Y,	  Ohkubo	  T,	  Furuichi	  Y,	  Umekawa	  H	  (2002)	  Tryptophans	  286	  and	  288	  in	   the	   C-­‐terminal	   region	   of	   protein	   B23.1	   are	   important	   for	   its	   nucleolar	  localization.	  Biosci	  Biotechnol	  Biochem	  66:	  2239-­‐2242	  	  Nozawa	   Y,	   Van	   Belzen	   N,	   Van	   der	   Made	   AC,	   Dinjens	   WN,	   Bosman	   FT	   (1996)	  Expression	  of	   nucleophosmin/B23	   in	  normal	   and	  neoplastic	   colorectal	  mucosa.	   J	  
Pathol	  178:	  48-­‐52	  	  Okada	  S,	  Nakauchi	  H,	  Nagayoshi	  K,	  Nishikawa	  S,	  Miura	  Y,	  Suda	  T	  (1992)	  In	  vivo	  and	  in	  vitro	  stem	  cell	  function	  of	  c-­‐kit-­‐	  and	  Sca-­‐1-­‐positive	  murine	  hematopoietic	  cells.	  
Blood	  80:	  3044-­‐3050	  	  Oki	   Y,	   Jelinek	   J,	   Beran	  M,	   Verstovsek	   S,	   Kantarjian	  HM,	   Issa	   JP	   (2006)	  Mutations	  and	   promoter	   methylation	   status	   of	   NPM1	   in	   myeloproliferative	   disorders.	  
Haematologica	  91:	  1147-­‐1148	  	  Okuda	  M,	  Horn	  HF,	  Tarapore	  P,	  Tokuyama	  Y,	   Smulian	  AG,	  Chan	  PK,	  Knudsen	  ES,	  Hofmann	   IA,	   Snyder	   JD,	   Bove	   KE,	   Fukasawa	   K	   (2000)	   Nucleophosmin/B23	   is	   a	  target	  of	  CDK2/cyclin	  E	  in	  centrosome	  duplication.	  Cell	  103:	  127-­‐140	  	  Okuwaki	   M,	   Matsumoto	   K,	   Tsujimoto	   M,	   Nagata	   K	   (2001)	   Function	   of	  nucleophosmin/B23,	  a	  nucleolar	  acidic	  protein,	  as	  a	  histone	  chaperone.	  FEBS	  Lett	  
506:	  272-­‐276	  
                                                                                                                 BIBLIOGRAPHY 
 
94	  
	  Olney	  HJ,	  Mitelman	  F,	  Johansson	  B,	  Mrozek	  K,	  Berger	  R,	  Rowley	  JD	  (2002)	  Unique	  balanced	   chromosome	   abnormalities	   in	   treatment-­‐related	   myelodysplastic	  syndromes	   and	   acute	  myeloid	   leukemia:	   report	   from	  an	   international	  workshop.	  
Genes	  Chromosomes	  Cancer	  33:	  413-­‐423	  	  Orazi	  A,	  Czader	  MB	  (2009)	  Myelodysplastic	  syndromes.	  Am	  J	  Clin	  Pathol	  132:	  290-­‐305	  	  Orford	   KW,	   Scadden	   DT	   (2008)	   Deconstructing	   stem	   cell	   self-­‐renewal:	   genetic	  insights	  into	  cell-­‐cycle	  regulation.	  Nat	  Rev	  Genet	  9:	  115-­‐128	  	  Osawa	   M,	   Hanada	   K,	   Hamada	   H,	   Nakauchi	   H	   (1996)	   Long-­‐term	  lymphohematopoietic	  reconstitution	  by	  a	  single	  CD34-­‐low/negative	  hematopoietic	  stem	  cell.	  Science	  273:	  242-­‐245	  	  Pabst	   T,	  Mueller	   BU,	   Zhang	   P,	   Radomska	  HS,	  Narravula	   S,	   Schnittger	   S,	   Behre	   G,	  Hiddemann	   W,	   Tenen	   DG	   (2001)	   Dominant-­‐negative	   mutations	   of	   CEBPA,	  encoding	  CCAAT/enhancer	  binding	  protein-­‐alpha	  (C/EBPalpha),	   in	  acute	  myeloid	  leukemia.	  Nat	  Genet	  27:	  263-­‐270	  	  Pang	  Q,	  Christianson	  TA,	  Koretsky	  T,	  Carlson	  H,	  David	  L,	  Keeble	  W,	  Faulkner	  GR,	  Speckhart	   A,	   Bagby	   GC	   (2003)	   Nucleophosmin	   interacts	   with	   and	   inhibits	   the	  catalytic	   function	   of	   eukaryotic	   initiation	   factor	   2	   kinase	   PKR.	   J	   Biol	   Chem	   278:	  41709-­‐41717	  	  Pang	  WW,	  Pluvinage	   JV,	  Price	  EA,	  Sridhar	  K,	  Arber	  DA,	  Greenberg	  PL,	  Schrier	  SL,	  Park	   CY,	   Weissman	   IL	   (2013)	   Hematopoietic	   stem	   cell	   and	   progenitor	   cell	  mechanisms	   in	  myelodysplastic	   syndromes.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  110:	   3011-­‐3016	  	  Pasqualucci	  L,	  Liso	  A,	  Martelli	  MP,	  Bolli	  N,	  Pacini	  R,	  Tabarrini	  A,	  Carini	  M,	  Bigerna	  B,	  Pucciarini	  A,	  Mannucci	  R,	  Nicoletti	  I,	  Tiacci	  E,	  Meloni	  G,	  Specchia	  G,	  Cantore	  N,	  Di	  Raimondo	  F,	  Pileri	  S,	  Mecucci	  C,	  Mandelli	  F,	  Martelli	  MF,	  Falini	  B	  (2006)	  Mutated	  nucleophosmin	   detects	   clonal	   multilineage	   involvement	   in	   acute	   myeloid	  leukemia:	  Impact	  on	  WHO	  classification.	  Blood	  108:	  4146-­‐4155	  	  Passegue	   E,	   Wagers	   AJ,	   Giuriato	   S,	   Anderson	   WC,	   Weissman	   IL	   (2005)	   Global	  analysis	   of	   proliferation	   and	   cell	   cycle	   gene	   expression	   in	   the	   regulation	   of	  hematopoietic	  stem	  and	  progenitor	  cell	  fates.	  J	  Exp	  Med	  202:	  1599-­‐1611	  	  Peitz	  M,	  Pfannkuche	  K,	  Rajewsky	  K,	  Edenhofer	  F	  (2002)	  Ability	  of	  the	  hydrophobic	  FGF	   and	   basic	   TAT	   peptides	   to	   promote	   cellular	   uptake	   of	   recombinant	   Cre	  recombinase:	  a	  tool	  for	  efficient	  genetic	  engineering	  of	  mammalian	  genomes.	  Proc	  
Natl	  Acad	  Sci	  U	  S	  A	  99:	  4489-­‐4494	  	  Peloquin	  GL,	  Chen	  YB,	  Fathi	  AT	   (2013)	  The	  evolving	   landscape	   in	   the	   therapy	  of	  acute	  myeloid	  leukemia.	  Protein	  Cell	  4:	  735-­‐746	  	  
                                                                                                                 BIBLIOGRAPHY 
 
95	  
Popov	  N,	  Wanzel	  M,	  Madiredjo	  M,	  Zhang	  D,	  Beijersbergen	  R,	  Bernards	  R,	  Moll	  R,	  Elledge	  SJ,	  Eilers	  M	  (2007)	  The	  ubiquitin-­‐specific	  protease	  USP28	   is	   required	   for	  MYC	  stability.	  Nat	  Cell	  Biol	  9:	  765-­‐774	  	  Rau	  R,	  Brown	  P	  (2009)	  Nucleophosmin	  (NPM1)	  mutations	  in	  adult	  and	  childhood	  acute	  myeloid	   leukaemia:	   towards	  definition	  of	   a	  new	   leukaemia	  entity.	  Hematol	  
Oncol	  27:	  171-­‐181	  	  Reindl	  C,	  Bagrintseva	  K,	  Vempati	  S,	  Schnittger	  S,	  Ellwart	  JW,	  Wenig	  K,	  Hopfner	  KP,	  Hiddemann	   W,	   Spiekermann	   K	   (2006)	   Point	   mutations	   in	   the	   juxtamembrane	  domain	   of	   FLT3	   define	   a	   new	   class	   of	   activating	   mutations	   in	   AML.	   Blood	   107:	  3700-­‐3707	  	  Reya	  T,	  Morrison	  SJ,	  Clarke	  MF,	  Weissman	  IL	  (2001)	  Stem	  cells,	  cancer,	  and	  cancer	  stem	  cells.	  Nature	  414:	  105-­‐111	  	  Rosnet	   O,	   Schiff	   C,	   Pebusque	   MJ,	   Marchetto	   S,	   Tonnelle	   C,	   Toiron	   Y,	   Birg	   F,	  Birnbaum	   D	   (1993)	   Human	   FLT3/FLK2	   gene:	   cDNA	   cloning	   and	   expression	   in	  hematopoietic	  cells.	  Blood	  82:	  1110-­‐1119	  	  Ruddon	   RW,	   Bedows	   E	   (1997)	   Assisted	   protein	   folding.	   J	   Biol	   Chem	  272:	   3125-­‐3128	  	  Sambrook	  J,	  Russell	  DW	  (2001)	  Molecular	  cloning	  :	  a	  laboratory	  manual,	  3rd	  edn.	  Cold	  Spring	  Harbor,	  N.Y.:	  Cold	  Spring	  Harbor	  Laboratory	  Press.	  	  Savkur	  RS,	  Olson	  MO	  (1998)	  Preferential	  cleavage	  in	  pre-­‐ribosomal	  RNA	  byprotein	  B23	  endoribonuclease.	  Nucleic	  Acids	  Res	  26:	  4508-­‐4515	  	  Schessl	  C,	  Rawat	  VP,	  Cusan	  M,	  Deshpande	  A,	  Kohl	  TM,	  Rosten	  PM,	  Spiekermann	  K,	  Humphries	   RK,	   Schnittger	   S,	   Kern	   W,	   Hiddemann	   W,	   Quintanilla-­‐Martinez	   L,	  Bohlander	  SK,	  Feuring-­‐Buske	  M,	  Buske	  C	  (2005)	  The	  AML1-­‐ETO	  fusion	  gene	  and	  the	   FLT3	   length	  mutation	   collaborate	   in	   inducing	   acute	   leukemia	   in	  mice.	   J	   Clin	  
Invest	  115:	  2159-­‐2168	  	  Schlenk	  RF,	  Dohner	  K,	  Krauter	  J,	  Frohling	  S,	  Corbacioglu	  A,	  Bullinger	  L,	  Habdank	  M,	  Spath	  D,	  Morgan	  M,	  Benner	  A,	  Schlegelberger	  B,	  Heil	  G,	  Ganser	  A,	  Dohner	  H	  (2008)	  Mutations	   and	   treatment	   outcome	   in	   cytogenetically	   normal	   acute	   myeloid	  leukemia.	  N	  Engl	  J	  Med	  358:	  1909-­‐1918	  	  Schmidt-­‐Zachmann	  MS,	  Hugle-­‐Dorr	  B,	  Franke	  WW	  (1987)	  A	  constitutive	  nucleolar	  protein	  identified	  as	  a	  member	  of	  the	  nucleoplasmin	  family.	  Embo	  J	  6:	  1881-­‐1890	  	  Schnittger	  S,	  Bacher	  U,	  Haferlach	  C,	  Alpermann	  T,	  Dicker	  F,	  Sundermann	  J,	  Kern	  W,	  Haferlach	   T	   (2011)	   Characterization	   of	   NPM1-­‐mutated	   AML	   with	   a	   history	   of	  myelodysplastic	   syndromes	   or	  myeloproliferative	   neoplasms.	  Leukemia	  25:	   615-­‐621	  	  
                                                                                                                 BIBLIOGRAPHY 
 
96	  
Schnittger	  S,	  Kern	  W,	  Tschulik	  C,	  Weiss	  T,	  Dicker	  F,	  Falini	  B,	  Haferlach	  C,	  Haferlach	  T	  (2009)	  Minimal	  residual	  disease	  levels	  assessed	  by	  NPM1	  mutation-­‐specific	  RQ-­‐PCR	  provide	  important	  prognostic	  information	  in	  AML.	  Blood	  114:	  2220-­‐2231	  	  Shields	  LB,	  Gercel-­‐Taylor	  C,	  Yashar	  CM,	  Wan	  TC,	  Katsanis	  WA,	  Spinnato	  JA,	  Taylor	  DD	   (1997)	   Induction	   of	   immune	   responses	   to	   ovarian	   tumor	   antigens	   by	  multiparity.	  J	  Soc	  Gynecol	  Investig	  4:	  298-­‐304	  	  Shipitsin	   M,	   Polyak	   K	   (2008)	   The	   cancer	   stem	   cell	   hypothesis:	   in	   search	   of	  definitions,	  markers,	  and	  relevance.	  Lab	  Invest	  88:	  459-­‐463	  	  Siminovitch	   L,	   McCulloch	   EA,	   Till	   JE	   (1963)	   The	   Distribution	   of	   Colony-­‐Forming	  Cells	  among	  Spleen	  Colonies.	  J	  Cell	  Physiol	  62:	  327-­‐336	  	  Singh	   SK,	   Clarke	   ID,	   Terasaki	  M,	   Bonn	  VE,	  Hawkins	   C,	   Squire	   J,	   Dirks	   PB	   (2003)	  Identification	  of	  a	  cancer	  stem	  cell	   in	  human	  brain	   tumors.	  Cancer	  Res	  63:	  5821-­‐5828	  	  Slany	  RK	  (2009)	  The	  molecular	  biology	  of	  mixed	  lineage	  leukemia.	  Haematologica	  
94:	  984-­‐993	  	  Sorror	  ML,	  Appelbaum	  FR	  (2013)	  Risk	  assessment	  before	  allogeneic	  hematopoietic	  cell	   transplantation	   for	   older	   adults	   with	   acute	   myeloid	   leukemia.	   Expert	   Rev	  
Hematol	  6:	  547-­‐562	  	  Spangrude	  GJ,	  Heimfeld	  S,	  Weissman	  IL	  (1988)	  Purification	  and	  characterization	  of	  mouse	  hematopoietic	  stem	  cells.	  Science	  241:	  58-­‐62	  	  Spector	   DL,	   Ochs	   RL,	   Busch	   H	   (1984)	   Silver	   staining,	   immunofluorescence,	   and	  immunoelectron	  microscopic	   localization	   of	   nucleolar	   phosphoproteins	   B23	   and	  C23.	  Chromosoma	  90:	  139-­‐148	  	  Sportoletti	  P,	  Grisendi	  S,	  Majid	  SM,	  Cheng	  K,	  Clohessy	  JG,	  Viale	  A,	  Teruya-­‐Feldstein	  J,	   Pandolfi	   PP	   (2008)	   Npm1	   is	   a	   haploinsufficient	   suppressor	   of	   myeloid	   and	  lymphoid	  malignancies	  in	  the	  mouse.	  Blood	  111:	  3859-­‐3862	  	  Sportoletti	  P,	  Varasano	  E,	  Rossi	  R,	  Bereshchenko	  O,	  Cecchini	  D,	  Gionfriddo	  I,	  Bolli	  N,	  Tiacci	  E,	  Intermesoli	  T,	  Zanghi	  P,	  Masciulli	  A,	  Martelli	  MP,	  Falzetti	  F,	  Martelli	  MF,	  Falini	   B	   (2013)	   The	   human	   NPM1	   mutation	   A	   perturbs	   megakaryopoiesis	   in	   a	  conditional	  mouse	  model.	  Blood	  121:	  3447-­‐3458	  	  Subong	   EN,	   Shue	   MJ,	   Epstein	   JI,	   Briggman	   JV,	   Chan	   PK,	   Partin	   AW	   (1999)	  Monoclonal	   antibody	   to	   prostate	   cancer	   nuclear	   matrix	   protein	   (PRO:4-­‐216)	  recognizes	  nucleophosmin/B23.	  Prostate	  39:	  298-­‐304	  
                                                                                                                 BIBLIOGRAPHY 
 
97	  
Srinivas	  S,	  Watanabe	  T,	  Lin	  CS,	  William	  CM,	  Tanabe	  Y,	  Jessell	  TM,	  Costantini	  F	  (2001)	  Cre	  reporter	  strains	  produced	  by	  targeted	  insertion	  of	  EYFP	  and	  ECFP	  into	  the	  ROSA26	  locus.	  Developmental	  Biology	  1:4	  	  Swaminathan	  V,	  Kishore	  AH,	  Febitha	  KK,	  Kundu	  TK	  (2005)	  Human	  histone	  chaperone	  nucleophosmin	  enhances	  acetylation-­‐dependent	  chromatin	  transcription.	  Mol	  Cell	  Biol	  25:	  7534-­‐7545	  	  Szebeni	   A,	   Mehrotra	   B,	   Baumann	   A,	   Adam	   SA,	   Wingfield	   PT,	   Olson	   MO	   (1997)	  Nucleolar	  protein	  B23	  stimulates	  nuclear	  import	  of	  the	  HIV-­‐1	  Rev	  protein	  and	  NLS-­‐conjugated	  albumin.	  Biochemistry	  36:	  3941-­‐3949	  	  Szebeni	   A,	   Olson	   MO	   (1999)	   Nucleolar	   protein	   B23	   has	   molecular	   chaperone	  activities.	  Protein	  Sci	  8:	  905-­‐912	  	  Szilvassy	  SJ,	  Humphries	  RK,	  Lansdorp	  PM,	  Eaves	  AC,	  Eaves	  CJ	  (1990)	  Quantitative	  assay	   for	   totipotent	   reconstituting	   hematopoietic	   stem	   cells	   by	   a	   competitive	  repopulation	  strategy.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  87:	  8736-­‐8740	  	  Takahashi	  S.	  (2011)Current	  findings	  for	  recurring	  mutations	  in	  acute	  myeloid	  leukemia.J	  Hematol	  Oncol.4:36.	  	  Tan	  BT,	  Park	  CY,	  Ailles	  LE,	  Weissman	  IL	  (2006)	  The	  cancer	  stem	  cell	  hypothesis:	  a	  work	  in	  progress.	  Lab	  Invest	  86:	  1203-­‐1207	  
 	  Tanaka	   M,	   Sasaki	   H,	   Kino	   I,	   Sugimura	   T,	   Terada	   M	   (1992)	   Genes	   preferentially	  expressed	   in	   embryo	   stomach	   are	   predominantly	   expressed	   in	   gastric	   cancer.	  
Cancer	  Res	  52:	  3372-­‐3377	  	  Taussig	   DC,	   Vargaftig	   J,	   Miraki-­‐Moud	   F,	   Griessinger	   E,	   Sharrock	   K,	   Luke	   T,	  Lillington	  D,	  Oakervee	  H,	  Cavenagh	  J,	  Agrawal	  SG,	  Lister	  TA,	  Gribben	  JG,	  Bonnet	  D	  (2010)	  Leukemia-­‐initiating	  cells	  from	  some	  acute	  myeloid	  leukemia	  patients	  with	  mutated	  nucleophosmin	  reside	  in	  the	  CD34(-­‐)	  fraction.	  Blood	  115:	  1976-­‐1984	  	  Thiede	   C,	   Koch	   S,	   Creutzig	   E,	   Steudel	   C,	   Illmer	   T,	   Schaich	  M,	   Ehninger	   G	   (2006)	  Prevalence	  and	  prognostic	  impact	  of	  NPM1	  mutations	  in	  1485	  adult	  patients	  with	  acute	  myeloid	  leukemia	  (AML).	  Blood	  107:	  4011-­‐4020	  	  Thorsteinsdottir	  U,	  Krosl	   J,	  Kroon	  E,	  Haman	  A,	  Hoang	  T,	  Sauvageau	  G	  (1999)	  The	  oncoprotein	   E2A-­‐Pbx1a	   collaborates	   with	   Hoxa9	   to	   acutely	   transform	   primary	  bone	  marrow	  cells.	  Mol	  Cell	  Biol	  19:	  6355-­‐6366	  	  Till	   JE,	  Mc	  CE	  (1961)	  A	  direct	  measurement	  of	  the	  radiation	  sensitivity	  of	  normal	  mouse	  bone	  marrow	  cells.	  Radiat	  Res	  14:	  213-­‐222	  	  Tsimberidou	  AM,	  Estey	  E	   (2006)	   Induction	  mortality	   risk	   in	   adult	   acute	  myeloid	  leukemia.	  Leuk	  Lymphoma	  47:	  1199-­‐1200	  	  
                                                                                                                 BIBLIOGRAPHY 
 
98	  
Tsui	   KH,	   Cheng	   AJ,	   Chang	   P,	   Pan	   TL,	   Yung	   BY	   (2004)	   Association	   of	  nucleophosmin/B23	   mRNA	   expression	   with	   clinical	   outcome	   in	   patients	   with	  bladder	  carcinoma.	  Urology	  64:	  839-­‐844	  	  Valdez	  BC,	  Perlaky	  L,	  Henning	  D,	  Saijo	  Y,	  Chan	  PK,	  Busch	  H	  (1994)	  Identification	  of	  the	  nuclear	  and	  nucleolar	  localization	  signals	  of	  the	  protein	  p120.	  Interaction	  with	  translocation	  protein	  B23.	  J	  Biol	  Chem	  269:	  23776-­‐23783	  	  Vassiliou	   GS,	   Cooper	   JL,	   Rad	   R,	   Li	   J,	   Rice	   S,	   Uren	   A,	   Rad	   L,	   Ellis	   P,	   Andrews	   R,	  Banerjee	  R,	  Grove	  C,	  Wang	  W,	  Liu	  P,	  Wright	  P,	  Arends	  M,	  Bradley	  A	  (2011)	  Mutant	  nucleophosmin	   and	   cooperating	   pathways	   drive	   leukemia	   initiation	   and	  progression	  in	  mice.	  Nat	  Genet	  43:	  470-­‐475	  	  Verfaillie	  CM	  (2002)	  Hematopoietic	  stem	  cells	  for	  transplantation.	  Nat	  Immunol	  3:	  314-­‐317	  	  Viale	  A,	  De	  Franco	  F,	  Orleth	  A,	  Cambiaghi	  V,	  Giuliani	  V,	  Bossi	  D,	  Ronchini	  C,	  Ronzoni	  S,	  Muradore	  I,	  Monestiroli	  S,	  Gobbi	  A,	  Alcalay	  M,	  Minucci	  S,	  Pelicci	  PG	  (2009)	  Cell-­‐cycle	  restriction	  limits	  DNA	  damage	  and	  maintains	  self-­‐renewal	  of	  leukaemia	  stem	  cells.	  Nature	  457:	  51-­‐56	  	  Vogelstein	   B,	   Fearon	   ER,	   Hamilton	   SR,	   Kern	   SE,	   Preisinger	   AC,	   Leppert	   M,	  Nakamura	   Y,	   White	   R,	   Smits	   AM,	   Bos	   JL	   (1988)	   Genetic	   alterations	   during	  colorectal-­‐tumor	  development.	  N	  Engl	  J	  Med	  319:	  525-­‐532	  	  Wang	   D,	   Umekawa	   H,	   Olson	  MO	   (1993)	   Expression	   and	   subcellular	   locations	   of	  two	  forms	  of	  nucleolar	  protein	  B23	  in	  rat	  tissues	  and	  cells.	  Cell	  Mol	  Biol	  Res	  39:	  33-­‐42	  	  Wang	  YY,	  Zhao	  LJ,	  Wu	  CF,	  Liu	  P,	  Shi	  L,	  Liang	  Y,	  Xiong	  SM,	  Mi	  JQ,	  Chen	  Z,	  Ren	  R,	  Chen	  SJ	   (2011)	  C-­‐KIT	  mutation	   cooperates	  with	   full-­‐length	  AML1-­‐ETO	   to	   induce	   acute	  myeloid	  leukemia	  in	  mice.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  108:	  2450-­‐2455	  	  Weissman	   IL	   (2000)	  Stem	  cells:	  units	  of	  development,	  units	  of	   regeneration,	  and	  units	  in	  evolution.	  Cell	  100:	  157-­‐168	  	  Welch	   JS,	   Ley	   TJ,	   Link	   DC,	   Miller	   CA,	   Larson	   DE,	   Koboldt	   DC,	   Wartman	   LD,	  Lamprecht	  TL,	  Liu	  F,	  Xia	  J,	  Kandoth	  C,	  Fulton	  RS,	  McLellan	  MD,	  Dooling	  DJ,	  Wallis	  JW,	   Chen	   K,	   Harris	   CC,	   Schmidt	   HK,	   Kalicki-­‐Veizer	   JM,	   Lu	   C,	   Zhang	   Q,	   Lin	   L,	  O'Laughlin	  MD,	  McMichael	   JF,	  Delehaunty	  KD,	  Fulton	  LA,	  Magrini	  VJ,	  McGrath	  SD,	  Demeter	  RT,	  Vickery	  TL,	  Hundal	  J,	  Cook	  LL,	  Swift	  GW,	  Reed	  JP,	  Alldredge	  PA,	  Wylie	  TN,	   Walker	   JR,	   Watson	   MA,	   Heath	   SE,	   Shannon	   WD,	   Varghese	   N,	   Nagarajan	   R,	  Payton	   JE,	   Baty	   JD,	   Kulkarni	   S,	   Klco	   JM,	   Tomasson	  MH,	  Westervelt	   P,	  Walter	  MJ,	  Graubert	   TA,	   DiPersio	   JF,	   Ding	   L,	   Mardis	   ER,	   Wilson	   RK	   (2012)	   The	   origin	   and	  evolution	  of	  mutations	  in	  acute	  myeloid	  leukemia.	  Cell	  150:	  264-­‐278	  	  Whitman	  SP,	  Archer	  KJ,	  Feng	  L,	  Baldus	  C,	  Becknell	  B,	  Carlson	  BD,	  Carroll	  AJ,	  Mrozek	  K,	   Vardiman	   JW,	   George	   SL,	   Kolitz	   JE,	   Larson	   RA,	   Bloomfield	   CD,	   Caligiuri	   MA	  (2001)	  Absence	   of	   the	  wild-­‐type	   allele	   predicts	   poor	   prognosis	   in	   adult	   de	   novo	  
                                                                                                                 BIBLIOGRAPHY 
 
99	  
acute	   myeloid	   leukemia	   with	   normal	   cytogenetics	   and	   the	   internal	   tandem	  duplication	  of	  FLT3:	  a	   cancer	  and	   leukemia	  group	  B	  study.	  Cancer	  Res	  61:	  7233-­‐7239	  	  Wilson	  A,	  Laurenti	  E,	  Oser	  G,	  van	  der	  Wath	  RC,	  Blanco-­‐Bose	  W,	  Jaworski	  M,	  Offner	  S,	   Dunant	   CF,	   Eshkind	   L,	   Bockamp	   E,	   Lio	   P,	   Macdonald	   HR,	   Trumpp	   A	   (2008)	  Hematopoietic	  stem	  cells	  reversibly	  switch	  from	  dormancy	  to	  self-­‐renewal	  during	  homeostasis	  and	  repair.	  Cell	  135:	  1118-­‐1129	  	  Wu	   AM,	   Till	   JE,	   Siminovitch	   L,	   McCulloch	   EA	   (1968)	   Cytological	   evidence	   for	   a	  relationship	  between	  normal	  hemotopoietic	   colony-­‐forming	   cells	   and	   cells	  of	   the	  lymphoid	  system.	  J	  Exp	  Med	  127:	  455-­‐464	  	  Wu	  MH,	  Yung	  BY	   (2002)	  UV	  stimulation	  of	  nucleophosmin/B23	  expression	   is	   an	  immediate-­‐early	  gene	  response	  induced	  by	  damaged	  DNA.	  J	  Biol	  Chem	  277:	  48234-­‐48240	  	  Xiao	   J,	   Zhang	   Z,	   Chen	   GG,	   Zhang	   M,	   Ding	   Y,	   Fu	   J,	   Li	   M,	   Yun	   JP	   (2009)	  Nucleophosmin/B23	  interacts	  with	  p21WAF1/CIP1	  and	  contributes	  to	  its	  stability.	  
Cell	  Cycle	  8:	  889-­‐895	  	  Yada	  M,	  Hatakeyama	  S,	  Kamura	  T,	  Nishiyama	  M,	  Tsunematsu	  R,	  Imaki	  H,	  Ishida	  N,	  Okumura	   F,	   Nakayama	   K,	   Nakayama	   KI	   (2004)	   Phosphorylation-­‐dependent	  degradation	   of	   c-­‐Myc	   is	  mediated	   by	   the	   F-­‐box	   protein	   Fbw7.	  Embo	   J	  23:	   2116-­‐2125	  	  Yamamoto	  Y,	  Kiyoi	  H,	  Nakano	  Y,	  Suzuki	  R,	  Kodera	  Y,	  Miyawaki	  S,	  Asou	  N,	  Kuriyama	  K,	  Yagasaki	  F,	  Shimazaki	  C,	  Akiyama	  H,	  Saito	  K,	  Nishimura	  M,	  Motoji	  T,	  Shinagawa	  K,	   Takeshita	   A,	   Saito	   H,	   Ueda	   R,	   Ohno	   R,	   Naoe	   T	   (2001)	   Activating	   mutation	   of	  D835	  within	  the	  activation	  loop	  of	  FLT3	  in	  human	  hematologic	  malignancies.	  Blood	  
97:	  2434-­‐2439	  	  Yamashita,	  Y.,	  Yuan,	  J.,	  Suetake,	  I.,	  Suzuki,	  H.,	  Ishikawa,	  Y.,	  Choi,	  Y.L.,	  Ueno,	  T.,	  Soda,	  M.,	   Hamada,	   T.,	   Haruta,	   H.,	   et	   al.	   (2010).	   Array-­‐based	   genomic	   resequencing	   of	  human	  leukemia.	  Oncogene	  29,	  3723–3731.	  	  Yoneda-­‐Kato	   N,	   Look	   AT,	   Kirstein	   MN,	   Valentine	   MB,	   Raimondi	   SC,	   Cohen	   KJ,	  Carroll	  AJ,	  Morris	  SW	  (1996)	  The	  t(3;5)(q25.1;q34)	  of	  myelodysplastic	  syndrome	  and	  acute	  myeloid	   leukemia	  produces	  a	  novel	   fusion	  gene,	  NPM-­‐MLF1.	  Oncogene	  
12:	  265-­‐275	  	  Yu	   Y,	   Maggi	   LB,	   Jr.,	   Brady	   SN,	   Apicelli	   AJ,	   Dai	   MS,	   Lu	   H,	   Weber	   JD	   (2006)	  Nucleophosmin	   is	  essential	   for	  ribosomal	  protein	  L5	  nuclear	  export.	  Mol	  Cell	  Biol	  
26:	  3798-­‐3809	  	  Yun	   C,	  Wang	   Y,	  Mukhopadhyay	   D,	   Backlund	   P,	   Kolli	   N,	   Yergey	   A,	  Wilkinson	   KD,	  Dasso	  M	   (2008)	   Nucleolar	   protein	   B23/nucleophosmin	   regulates	   the	   vertebrate	  SUMO	  pathway	  through	  SENP3	  and	  SENP5	  proteases.	  J	  Cell	  Biol	  183:	  589-­‐595	  	  
                                                                                                                 BIBLIOGRAPHY 
 
100	  
Yung	  BY,	  Busch	  H,	  Chan	  PK	  (1985)	  Translocation	  of	  nucleolar	  phosphoprotein	  B23	  (37	   kDa/pI	   5.1)	   induced	   by	   selective	   inhibitors	   of	   ribosome	   synthesis.	   Biochim	  
Biophys	  Acta	  826:	  167-­‐173	  	  Zhang	   Y,	   Zhang	   M,	   Yang	   L,	   Xiao	   Z	   (2007)	   NPM1	   mutations	   in	   myelodysplastic	  syndromes	  and	  acute	  myeloid	  leukemia	  with	  normal	  karyotype.	  Leuk	  Res	  31:	  109-­‐111	  	  Zhang	  Y,	  Zhang	  MR,	  Yang	  L,	  Xiao	  ZJ	  (2006)	  [Study	  of	  nucleophosmin	  (NPM)	  gene	  mutation	   in	   patients	   with	   acute	   myeloid	   leukemia	   and	   myelodysplastic	  syndromes].	  Zhonghua	  Xue	  Ye	  Xue	  Za	  Zhi	  27:	  470-­‐473	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
